{"meta":{"query_hash":"6cd95c356a07","filters":{"venue":"Seminars in Oncology"},"cohort_total":87,"direct_labels_cover":0,"predictions_cover":87,"exported":87,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/6cd95c356a07","api":"https://metacan.xera.ac/api/v1/cohort?venue=Seminars+in+Oncology"},"results":[{"id":"W1968524867","doi":"10.1053/j.seminoncol.2010.06.001","title":"Zoledronic Acid Use in Patients With Bone Metastases From Renal Cell Carcinoma or Bladder Cancer","year":2010,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Novartis Pharmaceuticals Corporation; Novartis","keywords":"Medicine; Zoledronic acid; Renal cell carcinoma; Cancer; Placebo; Internal medicine; Oncology; Bladder cancer; Bone disease; Urology; Kidney cancer; Surgery; Pathology; Osteoporosis","score_opus":0.042164820549838965,"score_gpt":0.3604882786700274,"score_spread":0.3183234581201885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968524867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005079225,0.99895453,0.00003453947,0.00008632426,0.000054077456,0.0000030352717,0.000034421817,0.0000032360933,0.00032197655],"genre_scores_gemma":[0.0057231705,0.9935882,0.000098161916,0.00020077768,0.00008282775,0.0000056912972,0.000062806845,7.134922e-7,0.00023764258],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987984,0.000020587706,0.000031213476,0.000019733574,0.000038380163,0.0000101883115],"domain_scores_gemma":[0.9998142,0.000094660034,0.000056746667,0.0000028909615,0.000022277995,0.000009218201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021928268,0.00042772805,0.0016845689,0.0011932481,0.00011004527,0.00038003392,0.00050380884,0.00045218482,0.0016706398],"category_scores_gemma":[0.0006239488,0.00017325066,0.00068986067,0.0016511698,0.00016431326,0.00030471323,0.00022989698,0.0004335571,0.00032628395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005511205,0.000053112588,0.0024030241,0.0483494,0.001144035,0.0004582796,0.000045170567,0.00038637358,0.0012417531,0.00040194063,0.015217615,0.92974824],"study_design_scores_gemma":[0.0016341455,0.0015594331,0.059495095,0.031446215,0.015342289,0.015958847,0.00033641793,0.00074594567,0.0022607497,0.0014002657,0.86969495,0.00012557545],"about_ca_topic_score_codex":0.0027778985,"about_ca_topic_score_gemma":0.009402742,"teacher_disagreement_score":0.0027778985,"about_ca_system_score_codex":0.00039496174,"about_ca_system_score_gemma":0.000833378,"threshold_uncertainty_score":0.0055888295},"labels":[],"label_agreement":null},{"id":"W1975826537","doi":"10.1053/j.seminoncol.2004.03.042","title":"The role of COX-2 inhibition in breast cancer treatment and prevention","year":2004,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":233,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Celecoxib; Aromatase; Breast cancer; Exemestane; Internal medicine; Oncology; Cancer; Angiogenesis; Cancer research","score_opus":0.0147704007122809,"score_gpt":0.3580283085129214,"score_spread":0.34325790780064047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975826537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001321918,0.99905413,0.000061519706,0.0001863645,0.00014182461,0.0000022450326,0.00001123732,0.0000033222461,0.00040708177],"genre_scores_gemma":[0.0009861726,0.99811435,0.00015127391,0.00016992538,0.00015442474,0.0000041847047,0.000017601957,7.9354317e-7,0.00040131065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987805,0.000024324227,0.000017826254,0.00001815347,0.000046638797,0.000014916354],"domain_scores_gemma":[0.99967694,0.0001682906,0.000053562806,0.000009657073,0.000067396824,0.000024216855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006262837,0.00066677126,0.0016331224,0.0012964334,0.00021269196,0.0007442406,0.0006980394,0.0008918441,0.0034432001],"category_scores_gemma":[0.00063130603,0.00025139356,0.00048503582,0.0016788746,0.0004083231,0.0009043244,0.0003874135,0.0016348228,0.0016049517],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033428098,0.00011920042,0.00022425919,0.010671453,0.00017267559,0.00024989498,0.000034511577,0.00037175996,0.002093883,0.0014608802,0.019112727,0.96515447],"study_design_scores_gemma":[0.00018484441,0.00044482952,0.002616431,0.003838968,0.0004451788,0.001675174,0.00008786521,0.00018314639,0.0012147893,0.0019634885,0.987317,0.00002816806],"about_ca_topic_score_codex":0.0013144717,"about_ca_topic_score_gemma":0.0040277676,"teacher_disagreement_score":0.0034432001,"about_ca_system_score_codex":0.0004601315,"about_ca_system_score_gemma":0.0008882123,"threshold_uncertainty_score":0.011518717},"labels":[],"label_agreement":null},{"id":"W1980747619","doi":"10.1053/j.seminoncol.2009.10.014","title":"Clinical Development of Temsirolimus, a Novel mTOR Inhibitor, for Treatment of Advanced Malignancies","year":2009,"lang":"en","type":"editorial","venue":"Seminars in Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Temsirolimus; Discovery and development of mTOR inhibitors; Medicine; PI3K/AKT/mTOR pathway; Sirolimus; Oncology; Cancer research; Internal medicine; Signal transduction","score_opus":0.023576499897532133,"score_gpt":0.371626267336534,"score_spread":0.34804976743900184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980747619","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000429061,0.0471874,0.00089826656,0.07306166,0.87242025,0.00006843473,0.00011102143,0.000111250374,0.0057125837],"genre_scores_gemma":[0.0037296382,0.03569402,0.0008052527,0.052708328,0.8840924,0.0000655472,0.00014254141,0.00004597111,0.022716261],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880064,0.00022532626,0.00018619343,0.00013529113,0.000541219,0.0001112484],"domain_scores_gemma":[0.9966744,0.0011984222,0.00019740193,0.00006225576,0.0012941465,0.0005734102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038535106,0.0017524267,0.001948635,0.0010672688,0.0008743048,0.002432986,0.0019059279,0.008155296,0.0034596059],"category_scores_gemma":[0.0059257755,0.0005477439,0.0015281818,0.00046648085,0.00088149443,0.0015535627,0.00055417215,0.012368596,0.0025881084],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022559968,0.000035849727,0.000045499408,0.00041422626,0.00004785298,0.00036913352,0.00001057142,0.000075370655,0.00046248967,0.0006055281,0.9669871,0.030720817],"study_design_scores_gemma":[0.00039489794,0.00020356741,0.0005202264,0.00029260528,0.00014417399,0.0008355378,0.000013062707,0.00030591342,0.0006692892,0.00059337984,0.99600583,0.000021549993],"about_ca_topic_score_codex":0.0008411654,"about_ca_topic_score_gemma":0.0023084714,"teacher_disagreement_score":0.008155296,"about_ca_system_score_codex":0.0015203739,"about_ca_system_score_gemma":0.0016145526,"threshold_uncertainty_score":0.020379603},"labels":[],"label_agreement":null},{"id":"W1984740505","doi":"10.1053/sonc.2002.30143","title":"Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma","year":2002,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Rituximab; Mantle cell lymphoma; Autologous stem-cell transplantation; Transplantation; Surgery; Cyclophosphamide; Internal medicine; Vincristine; Chemoimmunotherapy; Oncology; Debulking; Chemotherapy; Lymphoma; Cancer; Ovarian cancer","score_opus":0.016037350853888393,"score_gpt":0.26521463581250715,"score_spread":0.24917728495861877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984740505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.958501,0.014028542,0.0038244138,0.003911873,0.0008244072,0.0002780787,0.0001263004,0.00024306319,0.018262351],"genre_scores_gemma":[0.996077,0.00090227067,0.0008376788,0.0006140465,0.00039234603,0.000050858227,0.000103243256,0.00001249971,0.00101012],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99974304,0.000091293216,0.000029073262,0.00002444206,0.00003437154,0.00007779132],"domain_scores_gemma":[0.99959046,0.00021805882,0.000059612827,0.00004945269,0.000018942594,0.00006347084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079430867,0.00033047772,0.0006703441,0.0005171842,0.0005885827,0.0003820325,0.00046427987,0.0012594776,0.00085709704],"category_scores_gemma":[0.001430934,0.00017368683,0.0006129979,0.00024117414,0.00035632818,0.0005195987,0.0002963821,0.0015013018,0.00028270253],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06624809,0.011517935,0.07181557,0.0008177032,0.0011892724,0.13230868,0.00054075796,0.015847405,0.078086056,0.005726812,0.021307368,0.5945943],"study_design_scores_gemma":[0.017351393,0.08468978,0.4238543,0.00034960872,0.0019322976,0.25784597,0.00030111783,0.03208499,0.08969118,0.012206964,0.07942793,0.00026454407],"about_ca_topic_score_codex":0.00074615557,"about_ca_topic_score_gemma":0.0012897195,"teacher_disagreement_score":0.0012594776,"about_ca_system_score_codex":0.0005785716,"about_ca_system_score_gemma":0.0003348023,"threshold_uncertainty_score":0.0042007565},"labels":[],"label_agreement":null},{"id":"W1986647178","doi":"10.1016/s0093-7754(03)00171-4","title":"Treatment of cancer-related hypercalcemia: The role of gallium nitrate","year":2003,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Calcitonin; Bone resorption; Internal medicine; Endocrinology","score_opus":0.04123986567245706,"score_gpt":0.41195496175165386,"score_spread":0.3707150960791968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986647178","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018132846,0.9990331,0.00008491881,0.00022571276,0.00011126348,0.000003152427,0.0000062356958,0.0000051934508,0.00034911765],"genre_scores_gemma":[0.0011821622,0.9979558,0.00018327034,0.00024348451,0.00010876358,0.000004654636,0.000014047141,0.0000017721477,0.00030604086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998287,0.000037734768,0.000024949104,0.00003222231,0.000058974638,0.000017368051],"domain_scores_gemma":[0.99975926,0.00012621025,0.000046823367,0.0000074934533,0.000040529394,0.000019681955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005764694,0.00085859175,0.0026051905,0.0014086927,0.00022426558,0.0008455769,0.0011774747,0.0012154493,0.0019189076],"category_scores_gemma":[0.00054815883,0.00025945294,0.00077262765,0.0017801014,0.0005762505,0.0008321615,0.000519342,0.0019548305,0.0010149291],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041415135,0.00017199879,0.00018473288,0.011666183,0.00018069583,0.00039310489,0.000049407976,0.0003600609,0.0027133538,0.0013959212,0.019576646,0.9628937],"study_design_scores_gemma":[0.00044197883,0.00068624056,0.0024234627,0.0048715533,0.0005898356,0.0043686028,0.0001258823,0.00030986112,0.0021348284,0.0024706083,0.98152506,0.00005199612],"about_ca_topic_score_codex":0.0019048542,"about_ca_topic_score_gemma":0.004280614,"teacher_disagreement_score":0.0026051905,"about_ca_system_score_codex":0.0006089061,"about_ca_system_score_gemma":0.00090777926,"threshold_uncertainty_score":0.0064194202},"labels":[],"label_agreement":null},{"id":"W1988586595","doi":"10.1053/sonc.2003.50017","title":"Thoracic radiotherapy for limited-stage small cell lung cancer: Issues of timing, volumes, dose, and fractionation","year":2003,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Radiation therapy; Medicine; Chemotherapy; Dose fractionation; Randomized controlled trial; Oncology; Lung cancer; Stage (stratigraphy); Internal medicine; Surgery","score_opus":0.08208530181503791,"score_gpt":0.4927384745917523,"score_spread":0.41065317277671437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988586595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000089505505,0.99953055,0.00003934434,0.000100200414,0.000047950853,0.00000185887,0.0000026691432,0.000001465165,0.0001864852],"genre_scores_gemma":[0.0005648348,0.99901545,0.00010591022,0.00011678602,0.000052031126,0.0000033825752,0.0000053259037,5.8026205e-7,0.00013564467],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996929,0.00008983143,0.000048407215,0.000049960498,0.000100453326,0.000018454946],"domain_scores_gemma":[0.9993748,0.0004207671,0.00008680887,0.000015490305,0.00008539027,0.000016717608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016150828,0.000715985,0.0026989756,0.0011252901,0.00024713436,0.00073973153,0.001295103,0.0008955478,0.002063915],"category_scores_gemma":[0.0014826625,0.0002955133,0.00063598115,0.0026161761,0.0005656376,0.00090201123,0.00037797072,0.0010979081,0.00076712895],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019691908,0.000049668433,0.00027488792,0.021375677,0.00016548141,0.00014339332,0.000046167635,0.00040877637,0.0011269634,0.0008651023,0.008981416,0.9663657],"study_design_scores_gemma":[0.00028212406,0.0008905329,0.0060679773,0.017101958,0.0015130074,0.0045201797,0.0002867563,0.00019351898,0.001426989,0.0025326859,0.9651359,0.000048427617],"about_ca_topic_score_codex":0.0027905842,"about_ca_topic_score_gemma":0.008070012,"teacher_disagreement_score":0.0027905842,"about_ca_system_score_codex":0.00093722664,"about_ca_system_score_gemma":0.001578976,"threshold_uncertainty_score":0.008541465},"labels":[],"label_agreement":null},{"id":"W1991788040","doi":"10.1053/j.seminoncol.2007.10.006","title":"Clinical Benefits and Considerations of Bisphosphonate Treatment in Metastatic Bone Disease","year":2007,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Zoledronic acid; Prostate cancer; Breast cancer; Oncology; Multiple myeloma; Internal medicine; Bone pain; Bone disease; N-terminal telopeptide; Bone resorption; Bisphosphonate; Osteoporosis; Cancer; Alkaline phosphatase; Osteocalcin","score_opus":0.17224841962941687,"score_gpt":0.49897491703155994,"score_spread":0.3267264974021431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991788040","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005285852,0.9990403,0.000034902314,0.00034313244,0.00012590352,0.0000013833097,0.000005543803,0.0000016643357,0.0003942068],"genre_scores_gemma":[0.00077382184,0.9981554,0.00014991374,0.000419784,0.00026739313,0.0000031042237,0.0000103124885,7.074208e-7,0.00021951093],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995808,0.00010024292,0.000076177785,0.000046781537,0.00017068538,0.000025414507],"domain_scores_gemma":[0.9991497,0.0005620061,0.00012713212,0.0000117854,0.000115686045,0.0000337261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013068713,0.000718674,0.002140408,0.0022145628,0.00029381845,0.0012980711,0.0010625123,0.001600689,0.0031936576],"category_scores_gemma":[0.0018871749,0.00033208623,0.00071408384,0.002240932,0.0006909434,0.0011141299,0.00049194455,0.0023351081,0.0011518082],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025600506,0.00007352864,0.00030640292,0.02155997,0.00021722393,0.00055518054,0.000053264903,0.00044092786,0.0008327958,0.0041566156,0.03450971,0.9370384],"study_design_scores_gemma":[0.00017178878,0.00021381765,0.00240913,0.015439562,0.0007331315,0.0047841165,0.0001403282,0.0002476922,0.0004051549,0.004378056,0.97103745,0.00003987212],"about_ca_topic_score_codex":0.0014772902,"about_ca_topic_score_gemma":0.0051228274,"teacher_disagreement_score":0.0031936576,"about_ca_system_score_codex":0.0008872324,"about_ca_system_score_gemma":0.0011620478,"threshold_uncertainty_score":0.010683835},"labels":[],"label_agreement":null},{"id":"W1994549184","doi":"10.1053/j.seminoncol.2010.05.008","title":"The Role of Physical Activity in Breast Cancer Etiology","year":2010,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Physical Activity and Health","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Breast cancer; Observational study; Population; Cancer; Randomized controlled trial; Epidemiology; Cancer prevention; Incidence (geometry); Gerontology; Internal medicine; Demography; Physical therapy; Environmental health","score_opus":0.03902035306381191,"score_gpt":0.43838135601563033,"score_spread":0.3993610029518184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994549184","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000054364533,0.99949276,0.000027985905,0.00011722778,0.00007801439,0.0000013514184,0.000007805313,0.000001329679,0.00021918918],"genre_scores_gemma":[0.00044554687,0.999212,0.00005244068,0.00007916161,0.00009462973,0.0000018028571,0.0000128896945,3.928603e-7,0.000101075304],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997385,0.00005386224,0.000047296904,0.00005622938,0.000082868886,0.000021219543],"domain_scores_gemma":[0.9993643,0.00040446562,0.00009764922,0.000011932493,0.00009428731,0.000027329223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008060037,0.0010454829,0.0022032724,0.0024583135,0.00024261953,0.0011306814,0.000985998,0.0012282571,0.0030592955],"category_scores_gemma":[0.0012468583,0.0004195039,0.0008790838,0.0034577404,0.00066641584,0.0012589865,0.0008879199,0.0016103389,0.001262158],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109878936,0.000072088136,0.0010308865,0.029027067,0.00042283544,0.00020287924,0.00005066856,0.00031144137,0.00049327704,0.0013893107,0.013580078,0.9533094],"study_design_scores_gemma":[0.00010210138,0.00021368626,0.0130077815,0.02689598,0.0015911544,0.0023187096,0.00029428862,0.0002974749,0.00042345363,0.003821603,0.95096666,0.000067157525],"about_ca_topic_score_codex":0.0033778995,"about_ca_topic_score_gemma":0.0055866945,"teacher_disagreement_score":0.0033778995,"about_ca_system_score_codex":0.00062251254,"about_ca_system_score_gemma":0.0015046404,"threshold_uncertainty_score":0.010234356},"labels":[],"label_agreement":null},{"id":"W1998463059","doi":"10.1053/j.seminoncol.2013.07.006","title":"Initial Treatment of Transplant Candidates With Multiple Myeloma","year":2013,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Thalidomide; Bortezomib; Autologous stem-cell transplantation; Oncology; Internal medicine; Toxicity; Transplantation; Surgery","score_opus":0.06313384381745932,"score_gpt":0.40425614925885506,"score_spread":0.34112230544139577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998463059","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042053335,0.998613,0.00010265577,0.00019582195,0.00012248242,0.0000041553426,0.000012812008,0.000004553947,0.000523997],"genre_scores_gemma":[0.0080346,0.98986685,0.0003835254,0.00081727933,0.0004306683,0.000010307595,0.000084251515,0.0000028935438,0.00036964708],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998516,0.000043911994,0.000025844904,0.000027721453,0.000033228043,0.000017624474],"domain_scores_gemma":[0.999688,0.00018692788,0.000063706284,0.0000060563075,0.000029546234,0.000025693482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033216382,0.0004415765,0.0013635149,0.0008761829,0.00020860166,0.0006067808,0.0006319146,0.00067951996,0.002779418],"category_scores_gemma":[0.0012013002,0.00016852898,0.0008545756,0.0005938596,0.00025501783,0.000486618,0.0003692716,0.0015031198,0.0006392496],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003969745,0.0001120251,0.0012563913,0.018327316,0.0002960221,0.0008346132,0.000052698993,0.00025340525,0.0010057305,0.0005385406,0.020193847,0.95673245],"study_design_scores_gemma":[0.0009065067,0.0014993601,0.026214922,0.050293453,0.0038235958,0.027883306,0.0004190285,0.0005286187,0.0025987176,0.0032863808,0.8824104,0.00013582838],"about_ca_topic_score_codex":0.0008097949,"about_ca_topic_score_gemma":0.0026626037,"teacher_disagreement_score":0.002779418,"about_ca_system_score_codex":0.00035934162,"about_ca_system_score_gemma":0.00062594714,"threshold_uncertainty_score":0.009298086},"labels":[],"label_agreement":null},{"id":"W1999139776","doi":"10.1016/s0093-7754(01)90077-6","title":"The importance of drug diversity in the treatment of small cell lung cancer","year":2001,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Etoposide; Cisplatin; Oncology; Lung cancer; Drug; Chemotherapy; Population; Internal medicine; Combination chemotherapy; Pharmacology","score_opus":0.03271828028642188,"score_gpt":0.3800493503969207,"score_spread":0.34733107011049885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999139776","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.781516,0.17219283,0.0031174254,0.017417865,0.00032855337,0.00010979847,0.0001886539,0.000024721168,0.02510407],"genre_scores_gemma":[0.97700673,0.020075241,0.00062239956,0.0009953423,0.00029892122,0.000018026085,0.00004036433,0.000005425312,0.0009374014],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981693,0.0011963805,0.00006839001,0.00011672172,0.00026085338,0.00018827827],"domain_scores_gemma":[0.99337995,0.0050210496,0.0006144217,0.00026991198,0.0002866506,0.00042798524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028848862,0.00011560596,0.00069455925,0.0007873249,0.00063048524,0.0012067851,0.00037815093,0.00044589778,0.0021117146],"category_scores_gemma":[0.005146931,0.000087241555,0.00027398538,0.0007018951,0.0014878268,0.0017622665,0.0009933757,0.00093602284,0.00013635907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009867241,0.0014004891,0.037676457,0.0015115577,0.00051830284,0.0004470142,0.0014713823,0.0057947244,0.06150737,0.04470313,0.0022416704,0.8328607],"study_design_scores_gemma":[0.0030827925,0.072139606,0.32056814,0.0015248242,0.0020118824,0.00792343,0.0064809015,0.0074750073,0.12793684,0.20067418,0.24997853,0.00020389444],"about_ca_topic_score_codex":0.0007365061,"about_ca_topic_score_gemma":0.0014398271,"teacher_disagreement_score":0.0028848862,"about_ca_system_score_codex":0.0008058578,"about_ca_system_score_gemma":0.0009762369,"threshold_uncertainty_score":0.015256882},"labels":[],"label_agreement":null},{"id":"W2000894976","doi":"10.1053/j.seminoncol.2005.07.017","title":"Brief Communication: A New Combination in the Treatment of Advanced Pancreatic Cancer","year":2005,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Medicine; Pancreatic cancer; Erlotinib; Oncology; Internal medicine; Chemotherapy; Cancer; Antimetabolite; Epidermal growth factor receptor","score_opus":0.038405063507172994,"score_gpt":0.40898494403717806,"score_spread":0.37057988053000507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000894976","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05234019,0.3113463,0.007162548,0.2500173,0.28298953,0.0006489939,0.0014436078,0.0006793215,0.093372196],"genre_scores_gemma":[0.17225505,0.15534917,0.008091598,0.15874049,0.37899107,0.00039835754,0.0012301567,0.00017603929,0.12476814],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.999443,0.00023605459,0.000058205038,0.000058823563,0.0001273277,0.000076530174],"domain_scores_gemma":[0.99923635,0.00045850547,0.00005888071,0.000033747787,0.0000712515,0.00014129127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010498741,0.0007602246,0.0014107891,0.0010235211,0.00079411233,0.0009693007,0.0006819402,0.004396634,0.012649795],"category_scores_gemma":[0.0013160512,0.0002150882,0.0010014023,0.0007390037,0.00064136076,0.0010836843,0.000416879,0.003665488,0.0029349518],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007031128,0.00059437373,0.0016980558,0.0018143298,0.000256455,0.01197517,0.00008233303,0.0006068521,0.0072374996,0.0026783145,0.54995114,0.41607434],"study_design_scores_gemma":[0.0023798763,0.0077652857,0.0067471727,0.00034908278,0.00046154507,0.016948178,0.00011063214,0.00074241764,0.006448121,0.0025336137,0.9554058,0.00010834964],"about_ca_topic_score_codex":0.00030975943,"about_ca_topic_score_gemma":0.0011817974,"teacher_disagreement_score":0.012649795,"about_ca_system_score_codex":0.000451416,"about_ca_system_score_gemma":0.00046307832,"threshold_uncertainty_score":0.042317808},"labels":[],"label_agreement":null},{"id":"W2002858168","doi":"10.1053/j.seminoncol.2003.12.002","title":"Integrating Monoclonal Antibodies into the Management of Mantle Cell Lymphoma","year":2004,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Rituximab; Mantle cell lymphoma; Autologous stem-cell transplantation; Oncology; Internal medicine; Transplantation; Chemotherapy; Clinical trial; Surgery; Maintenance therapy; Lymphoma","score_opus":0.011499077761637565,"score_gpt":0.3028536267254322,"score_spread":0.29135454896379465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002858168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38026822,0.4956436,0.025731046,0.044505913,0.004320293,0.00030299282,0.0000754164,0.00033247302,0.04882006],"genre_scores_gemma":[0.8784802,0.09247863,0.013313814,0.005923826,0.0070443945,0.00012565692,0.0000525141,0.000034886416,0.0025461551],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99968123,0.000110378365,0.000036756785,0.000022823895,0.0000940587,0.000054907185],"domain_scores_gemma":[0.99970007,0.00015031593,0.00003715811,0.000011221992,0.00003854025,0.00006278998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081245333,0.00034987094,0.00073747314,0.0007012218,0.00042699047,0.0007216095,0.00055050355,0.0009489174,0.0006652771],"category_scores_gemma":[0.0012837028,0.0001697445,0.00046437146,0.0003547903,0.0004231514,0.0006897844,0.0004339617,0.0021064868,0.00015536945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019317751,0.0009712224,0.020112924,0.0008415921,0.0002655468,0.011241541,0.00019253022,0.0041049244,0.016841846,0.0028716302,0.010041388,0.9305832],"study_design_scores_gemma":[0.006695747,0.027947187,0.24329765,0.003911068,0.0032119344,0.17695421,0.001588686,0.031336173,0.04204568,0.039301444,0.42336532,0.00034493074],"about_ca_topic_score_codex":0.0006384149,"about_ca_topic_score_gemma":0.0013782281,"teacher_disagreement_score":0.0009489174,"about_ca_system_score_codex":0.00046128323,"about_ca_system_score_gemma":0.0005494627,"threshold_uncertainty_score":0.00429672},"labels":[],"label_agreement":null},{"id":"W2003894443","doi":"10.1016/s0093-7754(01)90198-8","title":"Epirubicin in combination with the taxanes","year":2001,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Epirubicin; Medicine; Anthracycline; Cardiotoxicity; Taxane; Docetaxel; Doxorubicin; Breast cancer; Oncology; Metastatic breast cancer; Pharmacology; Internal medicine; Trastuzumab; Paclitaxel; Chemotherapy; Cancer","score_opus":0.020006710689128585,"score_gpt":0.3529680784910304,"score_spread":0.33296136780190183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003894443","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.960163,0.014369221,0.0025146217,0.0009080688,0.00038428933,0.00024891738,0.00040600658,0.00027365383,0.020732218],"genre_scores_gemma":[0.9841877,0.0043164706,0.0015038766,0.00010938437,0.00011518647,0.0000614768,0.00029483798,0.00002547908,0.009385583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998528,0.000071390234,0.0000061233495,0.000015340709,0.000024517985,0.000029857527],"domain_scores_gemma":[0.99990153,0.00003148007,0.00001166726,0.000013803579,0.0000061367086,0.00003545497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020652958,0.00033246225,0.00074314815,0.00044296507,0.00020228639,0.0002961561,0.00022090378,0.00019803403,0.0035902064],"category_scores_gemma":[0.0005426896,0.00013130634,0.00013133878,0.00035319052,0.00017921942,0.00029519794,0.00019571239,0.00075372116,0.0004490934],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04553323,0.0037911118,0.0023326164,0.00043650536,0.00028509213,0.0015069656,0.00029652868,0.003629912,0.39669347,0.003660399,0.00737779,0.5344564],"study_design_scores_gemma":[0.011106751,0.116167,0.049579885,0.0002196146,0.0005757989,0.012304914,0.00034013923,0.009212844,0.6194722,0.0037781016,0.1771274,0.00011526833],"about_ca_topic_score_codex":0.0005541476,"about_ca_topic_score_gemma":0.0023214524,"teacher_disagreement_score":0.0035902064,"about_ca_system_score_codex":0.00019814662,"about_ca_system_score_gemma":0.0003220798,"threshold_uncertainty_score":0.0120103955},"labels":[],"label_agreement":null},{"id":"W2004731110","doi":"10.1053/sonc.2003.50016","title":"Surgical treatment of small cell lung cancer","year":2003,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Chemoradiotherapy; Radiation therapy; Lung cancer; Chemotherapy; Surgery; Clinical trial; Oncology; Internal medicine","score_opus":0.07881713051370332,"score_gpt":0.48020935050552593,"score_spread":0.4013922199918226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004731110","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000063490894,0.999546,0.000018398148,0.00005740018,0.00006246462,0.0000018971537,0.000004307962,0.0000011614787,0.00024492343],"genre_scores_gemma":[0.00063316367,0.9989561,0.00004897861,0.00012552174,0.00007727376,0.0000024188257,0.000009738028,3.934232e-7,0.00014643397],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99974006,0.000067546694,0.00005137256,0.000048960144,0.00007327211,0.000018753983],"domain_scores_gemma":[0.99946874,0.00034989268,0.00009045528,0.000011896832,0.000056996138,0.000022056438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007461836,0.00072317367,0.001871988,0.0020686975,0.00025517886,0.0007423872,0.0007851589,0.00079404534,0.0029247012],"category_scores_gemma":[0.0012177593,0.0002548494,0.0008690374,0.002348309,0.0005666669,0.00076576613,0.00038769728,0.0010057014,0.00076514576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017515944,0.000071082366,0.0003696114,0.052739177,0.00036074925,0.0002760911,0.000044122073,0.00029054133,0.00076554524,0.0009865022,0.017725896,0.92619556],"study_design_scores_gemma":[0.0002465842,0.0005818578,0.0060535404,0.03223165,0.001952542,0.0043399716,0.00030270504,0.00013490056,0.00081004086,0.0015676441,0.95173204,0.000046513585],"about_ca_topic_score_codex":0.002157348,"about_ca_topic_score_gemma":0.006452121,"teacher_disagreement_score":0.0029247012,"about_ca_system_score_codex":0.0006220473,"about_ca_system_score_gemma":0.001016077,"threshold_uncertainty_score":0.009784102},"labels":[],"label_agreement":null},{"id":"W2011129605","doi":"10.1053/j.seminoncol.2010.06.007","title":"Maintaining Bone Health in Prostate Cancer Throughout the Disease Continuum","year":2010,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Zoledronic acid; Prostate cancer; Malignancy; Androgen deprivation therapy; Bone disease; Bone pain; Bisphosphonate; Bone metastasis; Cancer; Multiple myeloma; Disease; Bone Density Conservation Agents; Oncology; Internal medicine; Prostate; Osteoporosis; Surgery; Bone density","score_opus":0.04502589025133711,"score_gpt":0.4682166791827064,"score_spread":0.42319078893136924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011129605","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025919133,0.99950683,0.000025494213,0.00016551245,0.000072116214,0.0000013162759,0.0000036289446,0.0000016783117,0.00019756911],"genre_scores_gemma":[0.00027153137,0.9992799,0.00007021517,0.00014156286,0.00009108729,0.0000021316337,0.0000068899153,4.1770187e-7,0.00013627113],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996989,0.000065052,0.000042166,0.000046679565,0.000122068865,0.000025214105],"domain_scores_gemma":[0.99939823,0.0003687323,0.00008280561,0.000011544052,0.00010064183,0.000037981812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095554476,0.0009707785,0.0024520692,0.0022111456,0.00036996382,0.0011916573,0.0011613574,0.0016665229,0.003274285],"category_scores_gemma":[0.0012545652,0.00041627797,0.0005616773,0.0031407422,0.00088782486,0.0014358241,0.0008658214,0.002580693,0.0015236768],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008699325,0.000079840924,0.00016987632,0.022266535,0.0001417388,0.000118914075,0.0000544874,0.0002961975,0.0006073841,0.0027249858,0.027570952,0.94588214],"study_design_scores_gemma":[0.00007798872,0.00014778177,0.0018945008,0.012808703,0.00034250598,0.0014169912,0.00016568604,0.00011836599,0.00028415627,0.0033735174,0.9793367,0.00003309776],"about_ca_topic_score_codex":0.003412664,"about_ca_topic_score_gemma":0.01091276,"teacher_disagreement_score":0.003412664,"about_ca_system_score_codex":0.0010118224,"about_ca_system_score_gemma":0.0018364639,"threshold_uncertainty_score":0.010953605},"labels":[],"label_agreement":null},{"id":"W2017801391","doi":"10.1016/s0093-7754(03)00348-8","title":"Conservative versus radical therapy of prostate cancer: how have recent advances in molecular markers and imaging enhanced our ability to prognosticate risk?","year":2003,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Prostate; Cancer; Internal medicine; Gynecology","score_opus":0.044790958423923326,"score_gpt":0.4334559548225279,"score_spread":0.3886649963986046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017801391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007842688,0.9989329,0.000040931423,0.0005629974,0.0002008011,9.023322e-7,0.0000048191732,0.000001542579,0.00017664836],"genre_scores_gemma":[0.0010314008,0.9977114,0.00012451995,0.0005682936,0.00039733492,0.000002285638,0.000010264072,9.558335e-7,0.00015350828],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995808,0.0001456184,0.00006127669,0.000073261544,0.000116779476,0.000022355085],"domain_scores_gemma":[0.9989178,0.0007394568,0.000095414696,0.000018076395,0.00017958257,0.000049702005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021320304,0.0008028578,0.003833949,0.001106047,0.00025930285,0.0012088576,0.0013081969,0.0014822121,0.0016645812],"category_scores_gemma":[0.0024179963,0.00023837392,0.0006596495,0.0015340449,0.0009507762,0.0016964403,0.00042395285,0.0024142058,0.000819431],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034271245,0.00004616375,0.0006449704,0.0119735105,0.00029139072,0.00017615485,0.000057348476,0.00021263656,0.0005011527,0.0026342375,0.023884766,0.9592348],"study_design_scores_gemma":[0.0002794808,0.00046630562,0.008073449,0.017021352,0.0013163922,0.0028756997,0.00047458932,0.00025733895,0.000447866,0.006933454,0.9617643,0.000089849374],"about_ca_topic_score_codex":0.0026390434,"about_ca_topic_score_gemma":0.0060240356,"teacher_disagreement_score":0.003833949,"about_ca_system_score_codex":0.0009994402,"about_ca_system_score_gemma":0.0014529341,"threshold_uncertainty_score":0.011275351},"labels":[],"label_agreement":null},{"id":"W2022141581","doi":"10.1053/j.seminoncol.2004.01.007","title":"Anti-insulin-like growth factor strategies in breast cancer","year":2004,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Insulin-like growth factor-binding protein; Insulin-like growth factor; Growth factor; Cancer research; Endocrinology; Internal medicine; Cancer; Receptor; Mammary gland; Oncology","score_opus":0.033445092926653076,"score_gpt":0.36105570669583,"score_spread":0.3276106137691769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022141581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010295464,0.9990011,0.000057887526,0.00014519805,0.00012834767,0.0000020764985,0.000005789517,0.0000037229017,0.00055306905],"genre_scores_gemma":[0.0008030418,0.99821836,0.00015469216,0.0002029492,0.00014696762,0.000004771456,0.000015802376,7.952305e-7,0.00045263043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998776,0.000024933579,0.000018286211,0.000021452517,0.000043096363,0.00001468271],"domain_scores_gemma":[0.99975437,0.0001594978,0.00002936876,0.0000063494176,0.0000340466,0.000016377791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006095312,0.0007823085,0.0013437913,0.0017449295,0.00022463195,0.0008483095,0.0007339085,0.00090171257,0.0031703461],"category_scores_gemma":[0.00062166975,0.0002260157,0.00040449286,0.0019230228,0.0004051226,0.0009872678,0.00037354324,0.0015090823,0.001469802],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015382428,0.00012616429,0.00019599368,0.009751555,0.000109308094,0.00035840555,0.00003668356,0.00034633774,0.0017049001,0.0021856865,0.020744521,0.9642866],"study_design_scores_gemma":[0.000096137876,0.0002313261,0.0014222309,0.0032976342,0.00025062196,0.002395415,0.00007805786,0.00011664878,0.00085697137,0.0016576495,0.9895778,0.00001960101],"about_ca_topic_score_codex":0.00093161874,"about_ca_topic_score_gemma":0.0024922465,"teacher_disagreement_score":0.0031703461,"about_ca_system_score_codex":0.00060393696,"about_ca_system_score_gemma":0.0005891897,"threshold_uncertainty_score":0.010605872},"labels":[],"label_agreement":null},{"id":"W2024032952","doi":"10.1016/s0093-7754(03)00228-8","title":"Critical issues in the clinical testing of cancer vaccines: summary of a panel discussion at a symposium entitled ?cancer vaccines: are they here yet?? conducted in Toronto, Canada, December 2002","year":2003,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Clinical endpoint; Population; Surrogate endpoint; Cancer; Intensive care medicine; Randomized controlled trial; Vaccine efficacy; Adjuvant; Cancer vaccine; Clinical study design; Vaccination; Oncology; Immunology; Internal medicine; Immunotherapy","score_opus":0.03454154447542431,"score_gpt":0.3639646830667037,"score_spread":0.3294231385912794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024032952","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005689281,0.07560358,0.0012351153,0.8729366,0.04747504,0.00017780326,0.00010491353,0.000024096214,0.0018739112],"genre_scores_gemma":[0.014835646,0.12702289,0.005586225,0.72199565,0.12236411,0.0005005984,0.00028484841,0.00008986664,0.007320157],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9703268,0.014429689,0.0036016149,0.0017701405,0.0074028857,0.0024688821],"domain_scores_gemma":[0.9120683,0.04777705,0.0062827067,0.0010893386,0.022791531,0.009991006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08103539,0.00180793,0.0023622056,0.0016533391,0.005976952,0.008992781,0.004714443,0.038457092,0.004184244],"category_scores_gemma":[0.08634273,0.0013952379,0.0028308695,0.0023199199,0.0045164316,0.007914327,0.0043064794,0.031110222,0.0013745892],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002535345,0.00011598217,0.0008723632,0.002363428,0.00012427512,0.0006678904,0.0020559127,0.0003289446,0.0011474923,0.0041664564,0.92163575,0.066267945],"study_design_scores_gemma":[0.00012602506,0.00018653953,0.0030008738,0.0034622904,0.00021061757,0.00042556104,0.0033668533,0.00018784506,0.0005580466,0.005335309,0.9830376,0.00010229705],"about_ca_topic_score_codex":0.010890368,"about_ca_topic_score_gemma":0.03922284,"teacher_disagreement_score":0.08103539,"about_ca_system_score_codex":0.009304512,"about_ca_system_score_gemma":0.026958415,"threshold_uncertainty_score":0.4285612},"labels":[],"label_agreement":null},{"id":"W2026309863","doi":"10.1053/j.seminoncol.2013.09.004","title":"Risk-Based Health Care, the Cancer Survivor, the Oncologist, and the Primary Care Physician","year":2013,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Centers for Disease Control and Prevention","keywords":"Survivorship curve; Medicine; Psychological intervention; Health care; Family medicine; Cancer survivorship; Quality of life (healthcare); Cancer survivor; Population; Cancer; MEDLINE; Intervention (counseling); Nursing; Environmental health; Internal medicine","score_opus":0.03204789974542294,"score_gpt":0.3751807080466998,"score_spread":0.34313280830127685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2026309863","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031479572,0.99863464,0.000018421615,0.00059768395,0.00017305366,0.0000030096214,0.0000057797765,0.0000014103364,0.0005346417],"genre_scores_gemma":[0.00048296902,0.9985678,0.00005106078,0.0004973529,0.00018763183,0.0000043974874,0.000009994722,3.4161232e-7,0.00019840298],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994061,0.00017240935,0.0000790072,0.0000632385,0.00023366082,0.00004563899],"domain_scores_gemma":[0.9986519,0.00086050294,0.0001856919,0.000015028476,0.0001984443,0.0000884091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010492752,0.0007864892,0.001664257,0.0020787506,0.00045147672,0.001237691,0.0010779,0.0019738316,0.0059284326],"category_scores_gemma":[0.0029184185,0.0003167629,0.00074909086,0.002662852,0.00055875734,0.0014521491,0.00093849556,0.0020782244,0.0009553727],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060787588,0.00006799187,0.000485304,0.051280115,0.00030861422,0.00013588424,0.000092533504,0.00013537706,0.00015827878,0.0038207513,0.08906333,0.854391],"study_design_scores_gemma":[0.000093535535,0.00006122813,0.0030252167,0.07724417,0.0005750652,0.001116703,0.00030890314,0.00007254916,0.00007883726,0.0023093345,0.9150868,0.000027617376],"about_ca_topic_score_codex":0.0054586637,"about_ca_topic_score_gemma":0.022389134,"teacher_disagreement_score":0.0059284326,"about_ca_system_score_codex":0.0017448498,"about_ca_system_score_gemma":0.0031344274,"threshold_uncertainty_score":0.019832551},"labels":[],"label_agreement":null},{"id":"W2029030461","doi":"10.1016/s0093-7754(01)90065-x","title":"Temozolomide for recurrent high-grade glioma","year":2001,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Temozolomide; Medicine; Anaplastic astrocytoma; Oncology; Glioma; Quality of life (healthcare); Internal medicine; Procarbazine; Lomustine; Progression-free survival; Clinical trial; Dacarbazine; Astrocytoma; Surgery; Chemotherapy; Vincristine; Cancer research","score_opus":0.06659751042198406,"score_gpt":0.4115713583895171,"score_spread":0.34497384796753305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029030461","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010844741,0.99716324,0.00018463992,0.00020699052,0.00017678214,0.0000091743495,0.00003617773,0.000015138688,0.001123356],"genre_scores_gemma":[0.005264171,0.9925921,0.00028444894,0.000261291,0.00012524895,0.000010226044,0.000076663164,0.0000031272436,0.0013827569],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999397,0.000012281572,0.000014227593,0.000011097402,0.000016905613,0.000005778588],"domain_scores_gemma":[0.99989355,0.000040973675,0.000033578388,0.000004776948,0.000018032726,0.00000906585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029194314,0.00048985105,0.0010756457,0.0009225968,0.00012646963,0.0003136326,0.0006039491,0.0003155822,0.0019270261],"category_scores_gemma":[0.0004009091,0.00012593232,0.00030698205,0.0013477762,0.00016141584,0.0004527043,0.00020144584,0.00049009343,0.00077737635],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019102289,0.000047912057,0.00017196954,0.0077033234,0.00013418777,0.00028499213,0.000025588406,0.00023255279,0.0014187618,0.00030969785,0.018313922,0.97116596],"study_design_scores_gemma":[0.0003110958,0.00092105387,0.005165112,0.0027097056,0.0010631188,0.0066788313,0.000073624775,0.0002863987,0.0028987294,0.0005889421,0.9792716,0.00003172511],"about_ca_topic_score_codex":0.0017685487,"about_ca_topic_score_gemma":0.0056466004,"teacher_disagreement_score":0.0019270261,"about_ca_system_score_codex":0.00039431354,"about_ca_system_score_gemma":0.0005180306,"threshold_uncertainty_score":0.0064465404},"labels":[],"label_agreement":null},{"id":"W2032836693","doi":"10.1053/j.seminoncol.2014.03.009","title":"Pharmacoeconomics of Cancer Therapies: Considerations With the Introduction of Biosimilars","year":2014,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Pharmacoeconomics; Innovator; Health care; Risk analysis (engineering); Reimbursement; Product (mathematics); Intensive care medicine; Business","score_opus":0.03854655976674012,"score_gpt":0.4049752124438392,"score_spread":0.3664286526770991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032836693","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000081163314,0.9949443,0.00031602013,0.0033933998,0.00034960045,0.000004453781,0.000009309552,0.000004810407,0.0008968697],"genre_scores_gemma":[0.0008263854,0.99608094,0.0006096964,0.0014272648,0.0006907794,0.000010855909,0.000011229229,0.0000028838083,0.0003401063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980805,0.00058281893,0.00021359962,0.00017173462,0.00087122916,0.0000802081],"domain_scores_gemma":[0.991655,0.005927623,0.0005617952,0.00013285586,0.0015271713,0.00019556258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052431724,0.0008744585,0.0024471297,0.0032492727,0.00038322582,0.0028655669,0.0015348829,0.0040445514,0.0026832381],"category_scores_gemma":[0.009100207,0.00046752585,0.0014745565,0.0043635773,0.0014833071,0.0039049438,0.000864047,0.0061418894,0.001149697],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006430661,0.00007070921,0.000260603,0.013033469,0.0001999426,0.00026339493,0.000111899615,0.0014077013,0.00051170023,0.033300743,0.041107275,0.9096682],"study_design_scores_gemma":[0.000029947469,0.00010485091,0.0010705722,0.012118412,0.00016029092,0.0013570677,0.00016500162,0.0005040303,0.00027739903,0.021975799,0.96219194,0.00004460904],"about_ca_topic_score_codex":0.0025090373,"about_ca_topic_score_gemma":0.003531301,"teacher_disagreement_score":0.0052431724,"about_ca_system_score_codex":0.0026998983,"about_ca_system_score_gemma":0.0035833165,"threshold_uncertainty_score":0.027728856},"labels":[],"label_agreement":null},{"id":"W2033893059","doi":"10.1053/j.seminoncol.2003.12.021","title":"Targeted molecules in small cell lung cancer","year":2004,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Imatinib mesylate; Cancer research; Tyrosine kinase; Targeted therapy; Cancer; Immunoconjugate; Clinical trial; Imatinib; Immunology; Oncology; Antibody; Pathology; Internal medicine; Receptor; Monoclonal antibody","score_opus":0.04207325589161267,"score_gpt":0.44114568123938175,"score_spread":0.3990724253477691,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033893059","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000632056,0.99895465,0.00008158549,0.00017235661,0.00024799502,0.000005433146,0.0000095686355,0.0000058400815,0.00045932646],"genre_scores_gemma":[0.0004960464,0.99829334,0.000114650196,0.00023994833,0.00016696849,0.000008425641,0.000014777874,9.066152e-7,0.0006648582],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982315,0.00003735474,0.000028413164,0.00003020916,0.000058824167,0.00002209692],"domain_scores_gemma":[0.99967206,0.00017733495,0.000050461807,0.000012081175,0.000061002625,0.000027117834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009308946,0.0011877583,0.0024969287,0.0027774968,0.00031381028,0.0012677907,0.00092676264,0.001490253,0.004041429],"category_scores_gemma":[0.00082410075,0.0004067198,0.00062800094,0.0030055442,0.0006886727,0.0017940585,0.0006785855,0.0018829494,0.0022630673],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020214441,0.00011037795,0.00012634177,0.019845232,0.00015655825,0.00028374922,0.00004604055,0.0004130218,0.0030623297,0.0025376142,0.049942795,0.9232738],"study_design_scores_gemma":[0.00009489592,0.000209135,0.0005580903,0.003076194,0.000317351,0.0011198847,0.000040782747,0.000076651435,0.000851044,0.00095885777,0.9926797,0.000017485176],"about_ca_topic_score_codex":0.001270049,"about_ca_topic_score_gemma":0.003341266,"teacher_disagreement_score":0.004041429,"about_ca_system_score_codex":0.0009850153,"about_ca_system_score_gemma":0.0012508776,"threshold_uncertainty_score":0.013519943},"labels":[],"label_agreement":null},{"id":"W2034666734","doi":"10.1016/s0093-7754(01)90261-1","title":"Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program","year":2001,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Zoledronic acid; Medicine; Bisphosphonate; Internal medicine; Clinical trial; Urology; Refractory (planetary science); Randomized controlled trial; Malignancy; Gastroenterology; Surgery; Osteoporosis","score_opus":0.128744099947459,"score_gpt":0.4871120132950055,"score_spread":0.3583679133475465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034666734","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004729695,0.9987184,0.00006252245,0.00018432394,0.00007135618,0.000009093775,0.000026636028,0.0000047619965,0.0004500082],"genre_scores_gemma":[0.0018447677,0.99731547,0.00023447027,0.00022326926,0.00005865934,0.000007847036,0.00005786447,9.3327304e-7,0.00025673615],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972206,0.000046876314,0.000059213715,0.000034134868,0.00011137026,0.000026210055],"domain_scores_gemma":[0.9991566,0.00042683474,0.00012361465,0.000017587416,0.00021069817,0.00006469096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016289745,0.00068520365,0.0016026779,0.0018683794,0.00013609836,0.00079770916,0.0009084283,0.00089617044,0.0016400558],"category_scores_gemma":[0.0011992884,0.000224711,0.0007530729,0.003196458,0.00034175054,0.00068786426,0.00034513127,0.0008989263,0.00064821664],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077531836,0.00019695896,0.00042401414,0.016033677,0.00023423432,0.0002171567,0.00004451971,0.0005107051,0.0014936931,0.0011174482,0.016765807,0.96218646],"study_design_scores_gemma":[0.0015115814,0.0021048004,0.01297383,0.00929838,0.0024070195,0.003523494,0.0001549992,0.0004512064,0.0027795238,0.0011693982,0.96356666,0.000059296613],"about_ca_topic_score_codex":0.0035325328,"about_ca_topic_score_gemma":0.008630145,"teacher_disagreement_score":0.0035325328,"about_ca_system_score_codex":0.0008794009,"about_ca_system_score_gemma":0.00202067,"threshold_uncertainty_score":0.008614957},"labels":[],"label_agreement":null},{"id":"W2038873999","doi":"10.1016/s0093-7754(02)70178-4","title":"Epoetin alfa in patients not on chemotherapy – Canadian data","year":2002,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Epoetin alfa; Chemotherapy; Oncology; Internal medicine","score_opus":0.04577747811867397,"score_gpt":0.32015250621143865,"score_spread":0.2743750280927647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038873999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5817641,0.08706741,0.0012325584,0.01317582,0.0007399171,0.00046403418,0.1505216,0.00010905142,0.16492553],"genre_scores_gemma":[0.9262691,0.025596749,0.0012208289,0.00335347,0.00022990094,0.00013518763,0.03730348,0.00008292804,0.00580839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733055,0.0004145213,0.0004202908,0.0003340997,0.0009956175,0.00050497794],"domain_scores_gemma":[0.98800886,0.0021641583,0.0020801872,0.00065298245,0.0056158355,0.0014779671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002015043,0.00040741754,0.0011242544,0.0013219581,0.0012868182,0.001301235,0.0010575675,0.0005833427,0.0060563306],"category_scores_gemma":[0.010407244,0.0002752135,0.0013232373,0.0075023924,0.0007072773,0.00060719537,0.00047238296,0.0012031811,0.00051893474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015002419,0.00023647776,0.75648254,0.002961378,0.002014663,0.00074133236,0.0009797534,0.001527955,0.0009915588,0.0042128046,0.10830837,0.10654073],"study_design_scores_gemma":[0.0015465281,0.00038515133,0.88816816,0.00082838285,0.001629686,0.0007670987,0.00073463446,0.00027553114,0.00050646916,0.00048101947,0.10456817,0.00010915446],"about_ca_topic_score_codex":0.9466238,"about_ca_topic_score_gemma":0.97664136,"teacher_disagreement_score":0.053376198,"about_ca_system_score_codex":0.0139005035,"about_ca_system_score_gemma":0.025597792,"threshold_uncertainty_score":0.107381046},"labels":[],"label_agreement":null},{"id":"W2044362858","doi":"10.1053/j.seminoncol.2009.10.010","title":"Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials","year":2009,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Temsirolimus; Medicine; Mantle cell lymphoma; Clinical trial; Oncology; Lymphoma; Sirolimus; Internal medicine; Cancer research; PI3K/AKT/mTOR pathway; Cancer; Discovery and development of mTOR inhibitors; Signal transduction; Biology","score_opus":0.38308368459419134,"score_gpt":0.596782249862561,"score_spread":0.21369856526836967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044362858","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003512288,0.9987662,0.0001612993,0.00024399035,0.000088939145,0.000017522747,0.000052469146,0.00000808151,0.00031036002],"genre_scores_gemma":[0.0023984408,0.9955983,0.00070020324,0.00067580584,0.0001314716,0.00003429249,0.00013004999,0.0000061111436,0.00032519738],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9996184,0.00009198723,0.0000962237,0.00007519065,0.000093048475,0.000025100373],"domain_scores_gemma":[0.99856865,0.0009220658,0.0002173151,0.000027952485,0.00019269178,0.00007121992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020540955,0.0011482424,0.00470753,0.0018360313,0.00021034728,0.0013709533,0.0015697179,0.0010214166,0.002252728],"category_scores_gemma":[0.0024887316,0.0004088051,0.0015032149,0.0025081888,0.0003846993,0.0011999632,0.00044829768,0.0014723606,0.0007281465],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009750548,0.0001018109,0.00037291314,0.024690578,0.0008448869,0.0001718899,0.000036109886,0.0006381425,0.0016864992,0.0005800789,0.019089993,0.9508121],"study_design_scores_gemma":[0.0028022556,0.0031981452,0.0066710683,0.030758757,0.010705373,0.003862953,0.00016089038,0.0009971194,0.003148426,0.0026491971,0.9348897,0.00015616608],"about_ca_topic_score_codex":0.0010590875,"about_ca_topic_score_gemma":0.0033468097,"teacher_disagreement_score":0.00470753,"about_ca_system_score_codex":0.00096416636,"about_ca_system_score_gemma":0.0013276835,"threshold_uncertainty_score":0.0108632445},"labels":[],"label_agreement":null},{"id":"W2045470396","doi":"10.1053/j.seminoncol.2012.09.004","title":"Selective T-Cell Depletion for Haplotype-Mismatched Allogeneic Stem Cell Transplantation","year":2012,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Medicine; Transplantation; Stem cell; Haplotype; Cell; Immunology; Cancer research; Genetics; Internal medicine; Gene; Biology; Genotype","score_opus":0.05291611413076512,"score_gpt":0.35306248216744235,"score_spread":0.3001463680366772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045470396","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003853833,0.9978635,0.00037236663,0.00016023326,0.00022390128,0.0000069450903,0.00002071731,0.000012136573,0.0009549018],"genre_scores_gemma":[0.0020488577,0.9962675,0.00036162848,0.00027803477,0.00017428548,0.00001428813,0.000051891075,0.000003053588,0.00080045755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999915,0.000013312504,0.000011607641,0.000015973665,0.000031771393,0.000012369143],"domain_scores_gemma":[0.99988353,0.0000570908,0.000019766156,0.0000046319005,0.000021352102,0.000013581933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046629945,0.0007500777,0.0011396261,0.0009246568,0.00014555745,0.0005816261,0.0008344595,0.0005684943,0.0021257843],"category_scores_gemma":[0.00033021127,0.00016796011,0.00028900514,0.00081085815,0.0003829335,0.0006277374,0.00047602103,0.0011855407,0.001510955],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001255345,0.00009462846,0.00014306088,0.0065184548,0.000060107133,0.00016003368,0.000017209426,0.00029768544,0.005586531,0.0018044055,0.016944557,0.96824783],"study_design_scores_gemma":[0.00010434193,0.00028856975,0.0013002877,0.0022181447,0.0002390106,0.0021566793,0.0000376046,0.0001772602,0.00510087,0.0017601431,0.98658955,0.00002752072],"about_ca_topic_score_codex":0.00034861706,"about_ca_topic_score_gemma":0.0010044685,"teacher_disagreement_score":0.0021257843,"about_ca_system_score_codex":0.0003321768,"about_ca_system_score_gemma":0.0004890115,"threshold_uncertainty_score":0.00711143},"labels":[],"label_agreement":null},{"id":"W2051674705","doi":"10.1053/sonc.2002.32904","title":"Doctor's dilemma: Incorporating tumor markers into clinical decision-making","year":2002,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Dilemma; Clinical decision making; Intensive care medicine; Oncology; Medical physics; Epistemology","score_opus":0.04443460594989301,"score_gpt":0.42330899374947184,"score_spread":0.3788743877995788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051674705","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061613596,0.008086101,0.014126821,0.95944333,0.005991655,0.000058265912,0.000047441237,0.000057416823,0.0060276217],"genre_scores_gemma":[0.49586374,0.020381548,0.12988892,0.32275102,0.027607419,0.000481405,0.000120932156,0.00015509008,0.0027500156],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.95938224,0.0333631,0.0017275886,0.0008908389,0.004027948,0.0006082446],"domain_scores_gemma":[0.81708044,0.15706453,0.00582861,0.002561918,0.0075097405,0.009954754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.058994327,0.00066254305,0.0018902646,0.0017528847,0.0028889587,0.0067998567,0.002895894,0.010703079,0.0046331515],"category_scores_gemma":[0.20780724,0.00077647466,0.0009661788,0.0010567376,0.010240117,0.010340056,0.004790386,0.018300887,0.0012003244],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011019844,0.0006895036,0.018009821,0.0015496943,0.00077132817,0.0029383362,0.006196806,0.006200315,0.00057483406,0.09838433,0.36568373,0.4978992],"study_design_scores_gemma":[0.0009585107,0.0006144996,0.006829854,0.0040562777,0.0004934,0.0055590486,0.007799548,0.0145332245,0.0006301054,0.7423855,0.21576479,0.0003752009],"about_ca_topic_score_codex":0.001813956,"about_ca_topic_score_gemma":0.003062332,"teacher_disagreement_score":0.058994327,"about_ca_system_score_codex":0.0033644212,"about_ca_system_score_gemma":0.011553917,"threshold_uncertainty_score":0.3119955},"labels":[],"label_agreement":null},{"id":"W2051864325","doi":"10.1053/j.seminoncol.2009.07.008","title":"Colorectal Cancer in Young Adults","year":2009,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Disease; Colorectal cancer; Etiology; Population; Young adult; Stage (stratigraphy); Cancer; Presentation (obstetrics); Oncology; Internal medicine; Pediatrics; Gerontology; Intensive care medicine; Surgery","score_opus":0.02743801909510224,"score_gpt":0.39453083839613046,"score_spread":0.3670928193010282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051864325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017427703,0.99928397,0.000011950745,0.00012247848,0.000086992244,0.0000051970937,0.000024260049,0.0000013937203,0.00028948233],"genre_scores_gemma":[0.0014477791,0.998044,0.00004755086,0.00021007193,0.00007345763,0.0000068472878,0.000019553825,2.9708644e-7,0.00015036033],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997085,0.000082205996,0.000079181234,0.00003723267,0.00007021896,0.000022776767],"domain_scores_gemma":[0.99915373,0.00045025116,0.0002769501,0.000011372076,0.00006824574,0.000039474027],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067821343,0.00061684457,0.0019457956,0.0033687714,0.0001838978,0.0007078713,0.00035375095,0.0006387027,0.0044540954],"category_scores_gemma":[0.0021044281,0.00029516415,0.0008460125,0.0040121507,0.00029366472,0.0008106364,0.00069448777,0.00050160417,0.0004905],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019210721,0.00003652178,0.0018547333,0.14573298,0.0007979084,0.00025923137,0.000111865396,0.000091340116,0.00041111268,0.00046739454,0.023708833,0.82633597],"study_design_scores_gemma":[0.00036011386,0.0005396772,0.029537626,0.2564659,0.008459127,0.004520723,0.00059362774,0.000120213925,0.00055282505,0.00087847817,0.697914,0.000057687634],"about_ca_topic_score_codex":0.004125202,"about_ca_topic_score_gemma":0.014463015,"teacher_disagreement_score":0.0044540954,"about_ca_system_score_codex":0.0006312179,"about_ca_system_score_gemma":0.0016450877,"threshold_uncertainty_score":0.014900446},"labels":[],"label_agreement":null},{"id":"W2053652371","doi":"10.1053/j.seminoncol.2013.12.008","title":"Genes and Pathology of Non-Small Cell Lung Carcinoma","year":2013,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Lung cancer; Adenocarcinoma; Context (archaeology); Histopathology; Pathology; Molecular pathology; Carcinoma; Lung; Pathological; Oncology; Cancer; Internal medicine; Bioinformatics; Gene; Biology; Genetics","score_opus":0.027016335082217544,"score_gpt":0.38322859187598013,"score_spread":0.35621225679376256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053652371","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006972733,0.9989705,0.0000701621,0.00022467446,0.000155562,0.0000015440073,0.000012682423,0.000004256434,0.0004909277],"genre_scores_gemma":[0.00058654835,0.998524,0.00010141903,0.00017776675,0.0002026705,0.0000018699552,0.000023867657,7.7339314e-7,0.0003810807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984646,0.000024154273,0.000024238221,0.000028210674,0.000059852628,0.000017119535],"domain_scores_gemma":[0.9997162,0.00015154558,0.000044898585,0.000008158507,0.000060585087,0.000018625668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041109085,0.0007233012,0.0011702942,0.0018023177,0.00017948226,0.0008473772,0.0007753001,0.00089238514,0.0023051384],"category_scores_gemma":[0.0006922243,0.0002739099,0.00040888612,0.0018561427,0.0005641376,0.0009284149,0.00052951,0.001206423,0.0012564582],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056861034,0.000035053963,0.00039553296,0.0096924715,0.000091216614,0.00030437624,0.000035916742,0.00039133162,0.0015176825,0.0021921957,0.041524325,0.9437631],"study_design_scores_gemma":[0.00002250306,0.00004439958,0.0017931322,0.00408,0.00022286146,0.0022117058,0.00007429584,0.000119830635,0.0005229489,0.0027393731,0.98814535,0.000023601271],"about_ca_topic_score_codex":0.0013851679,"about_ca_topic_score_gemma":0.0026183745,"teacher_disagreement_score":0.0023051384,"about_ca_system_score_codex":0.0006410552,"about_ca_system_score_gemma":0.001077227,"threshold_uncertainty_score":0.00771147},"labels":[],"label_agreement":null},{"id":"W2054571776","doi":"10.1053/sonc.2002.37470","title":"Pemetrexed in the treatment of non[ndash ]small cell lung cancer","year":2002,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pemetrexed; Medicine; Docetaxel; Oncology; Internal medicine; Lung cancer; Chemotherapy; Carboplatin; Regimen; Rash; Cisplatin","score_opus":0.04361158469312567,"score_gpt":0.4382746969562653,"score_spread":0.39466311226313966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054571776","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030010907,0.99840564,0.000105160085,0.00022305126,0.00014651722,0.000004770326,0.000012492363,0.0000060525604,0.000796229],"genre_scores_gemma":[0.0016231345,0.9971902,0.00018001895,0.00021344755,0.000130534,0.000005188965,0.000023227309,9.990871e-7,0.0006332625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988735,0.000025371803,0.00001674907,0.000020759448,0.000038402897,0.000011369416],"domain_scores_gemma":[0.9998242,0.00009908519,0.000029321276,0.0000044920803,0.000027798764,0.000015134206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048551458,0.00061849295,0.00154309,0.0012229566,0.00019484173,0.00051583257,0.00071825157,0.000729955,0.002400067],"category_scores_gemma":[0.0004951839,0.0001738371,0.00042046537,0.0015075252,0.00027201633,0.000765219,0.00028136908,0.0011780866,0.0011134922],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021554141,0.00007753003,0.00015237383,0.008894239,0.00014392851,0.00041094763,0.000027857253,0.00047179,0.0012339174,0.00091306237,0.016112598,0.9713463],"study_design_scores_gemma":[0.00025022207,0.00041438374,0.002890602,0.0034823553,0.00048045866,0.0047549177,0.000072378025,0.00029626238,0.0011870868,0.0013246281,0.9848183,0.000028421895],"about_ca_topic_score_codex":0.0014654121,"about_ca_topic_score_gemma":0.004068837,"teacher_disagreement_score":0.002400067,"about_ca_system_score_codex":0.00047791968,"about_ca_system_score_gemma":0.0005300935,"threshold_uncertainty_score":0.008029044},"labels":[],"label_agreement":null},{"id":"W2056080086","doi":"10.1053/sonc.2003.50061","title":"The malignant clone in Waldenstrom's macroglobulinemia","year":2003,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"clone (Java method); Waldenstrom macroglobulinemia; Macroglobulinemia; Immunoglobulin D; Immunology; Bone marrow; Medicine; Immunoglobulin M; Antibody; Immunoglobulin gene; CD20; Biology; Pathology; B cell; Immunoglobulin G; Multiple myeloma; Lymphoma; Genetics; Gene","score_opus":0.01666658269212918,"score_gpt":0.3431467620100544,"score_spread":0.3264801793179252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056080086","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9380941,0.030867245,0.0014643278,0.00406197,0.0008316288,0.000062957464,0.00017791541,0.00013268462,0.024307147],"genre_scores_gemma":[0.9908145,0.004872738,0.0004018504,0.0003709715,0.0015593577,0.000012242271,0.00006335469,0.000013688743,0.0018912989],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998419,0.00003417861,0.000022189342,0.000014888443,0.000039614428,0.000047227422],"domain_scores_gemma":[0.9994387,0.00027349027,0.000096141826,0.000040742412,0.000058867587,0.00009208365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035515768,0.00036221472,0.00035505017,0.001966422,0.00049839285,0.00079965824,0.00037710313,0.0014957751,0.0018341778],"category_scores_gemma":[0.0024216347,0.00037969032,0.00012347355,0.00059089315,0.0005997727,0.0010305233,0.0004997796,0.0006363753,0.0006458604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031016613,0.00016671307,0.1941427,0.00059452927,0.000055178254,0.6700388,0.001013642,0.00066846446,0.038722713,0.010470363,0.012793735,0.06823151],"study_design_scores_gemma":[0.00016178754,0.0005745341,0.12940703,0.00013789389,0.00015907842,0.8081086,0.0005047182,0.0017756536,0.015772391,0.006451063,0.036910467,0.00003675724],"about_ca_topic_score_codex":0.0005671027,"about_ca_topic_score_gemma":0.00048834493,"teacher_disagreement_score":0.001966422,"about_ca_system_score_codex":0.0003607188,"about_ca_system_score_gemma":0.00024029668,"threshold_uncertainty_score":0.0061359406},"labels":[],"label_agreement":null},{"id":"W2059936546","doi":"10.1053/j.seminoncol.2013.09.009","title":"Renal and Pulmonary Late Effects of Cancer Therapy","year":2013,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Intensive care medicine; Cancer; Chemotherapy; Disease; Radiation therapy; Hematopoietic stem cell transplantation; Epidemiology; Pulmonary toxicity; Kidney disease; Natural history; Pathogenesis; Transplantation; Oncology; Toxicity; Internal medicine; Immunology","score_opus":0.010838255025779396,"score_gpt":0.32742886632410473,"score_spread":0.31659061129832533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059936546","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8035878,0.114575155,0.007441113,0.0035342637,0.000351592,0.00016506798,0.001049849,0.0002926793,0.06900246],"genre_scores_gemma":[0.9819967,0.00584482,0.00064330344,0.00055725646,0.00039270907,0.000021781609,0.00039668567,0.00004120113,0.0101055],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993993,0.00027755075,0.000030796447,0.000043241576,0.00011389835,0.00013520836],"domain_scores_gemma":[0.99794024,0.00083729596,0.00042592766,0.00017636582,0.00025290356,0.00036726502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012040335,0.0002656428,0.0007057825,0.0006444781,0.0003518045,0.0009871207,0.00045485477,0.0005256116,0.005738702],"category_scores_gemma":[0.00208294,0.00016525127,0.0008476809,0.0003922513,0.00037951733,0.00044016843,0.00031994304,0.001206253,0.0006134637],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03345836,0.0026993495,0.3363509,0.0015111539,0.0014710075,0.032763552,0.0004765989,0.00244253,0.098327085,0.0122410655,0.0064178705,0.47184068],"study_design_scores_gemma":[0.00096943206,0.009605129,0.783958,0.00036749657,0.0015136063,0.066263884,0.00037369074,0.002496135,0.072482064,0.004312725,0.05759992,0.00005793081],"about_ca_topic_score_codex":0.001610621,"about_ca_topic_score_gemma":0.0025665406,"teacher_disagreement_score":0.005738702,"about_ca_system_score_codex":0.0010398494,"about_ca_system_score_gemma":0.0010007375,"threshold_uncertainty_score":0.019197881},"labels":[],"label_agreement":null},{"id":"W2062119453","doi":"10.1053/j.seminoncol.2013.01.001","title":"Exercise Therapy as Treatment for Cardiovascular and Oncologic Disease After a Diagnosis of Early-Stage Cancer","year":2013,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Cancer; Disease; Adjuvant therapy; Stage (stratigraphy); Internal medicine; Intensive care medicine; Oncology","score_opus":0.07458153917372895,"score_gpt":0.3985226177539175,"score_spread":0.32394107858018856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062119453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001039031,0.99944764,0.000032169817,0.00007226173,0.000077684796,0.0000028888296,0.000007973226,0.0000017966975,0.00025370115],"genre_scores_gemma":[0.0009279097,0.9985613,0.00009967353,0.00011614329,0.00010116971,0.0000042848797,0.000016730384,6.445664e-7,0.00017209514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988806,0.000020003308,0.000021670705,0.000022572469,0.000037205704,0.000010463591],"domain_scores_gemma":[0.9997223,0.0001757729,0.000046469497,0.0000051172956,0.000036362944,0.0000140093125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038815083,0.0006810929,0.0016686425,0.0013828725,0.0001773314,0.0006186312,0.0007287112,0.00072913495,0.0025164208],"category_scores_gemma":[0.00059954304,0.00019999973,0.0006262921,0.0012108133,0.0003083022,0.00055541296,0.00041454684,0.00142143,0.00076366554],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014707843,0.00014226131,0.0002905365,0.02896553,0.00028750542,0.00016966638,0.000035945082,0.0002625705,0.00096254743,0.0010200547,0.010620226,0.95709616],"study_design_scores_gemma":[0.00025134455,0.00061088055,0.007002802,0.03264824,0.0016655646,0.003091221,0.00020604789,0.00030869362,0.0010363065,0.0026650964,0.9504486,0.00006521238],"about_ca_topic_score_codex":0.0012026076,"about_ca_topic_score_gemma":0.0036177402,"teacher_disagreement_score":0.0025164208,"about_ca_system_score_codex":0.00036084143,"about_ca_system_score_gemma":0.0006263488,"threshold_uncertainty_score":0.008418262},"labels":[],"label_agreement":null},{"id":"W2063044382","doi":"10.1053/sonc.2002.37418","title":"Treatment of bone complications in advanced prostate cancer: Rationale for bisphosphonate use and results of a phase III trial with zoledronic acid","year":2002,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Zoledronic acid; Medicine; Prostate cancer; Bisphosphonate; Bone pain; Bone disease; Cancer; Internal medicine; Oncology; Surgery; Urology; Osteoporosis","score_opus":0.08148374553096663,"score_gpt":0.4323332133059353,"score_spread":0.3508494677749687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063044382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00081158936,0.99849725,0.00006966911,0.0001968556,0.00008497968,0.000018623155,0.00003047042,0.00000480561,0.00028580465],"genre_scores_gemma":[0.004795499,0.9938544,0.00033827234,0.00058620435,0.00009760898,0.000023043596,0.000067639754,0.0000020960863,0.00023525368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997515,0.00006489048,0.00004814045,0.000042494903,0.000073655196,0.000019313587],"domain_scores_gemma":[0.99951017,0.00031227138,0.00008536796,0.000010929558,0.000056395835,0.00002490175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011824205,0.00069274066,0.0031386528,0.0009787257,0.00016973511,0.0006927536,0.0010879749,0.00095513347,0.0017732203],"category_scores_gemma":[0.0009812205,0.00025195698,0.0013154912,0.0015135319,0.00029492337,0.00040201432,0.00021446322,0.0013263607,0.0004030014],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002614805,0.0002466083,0.0005196968,0.039197538,0.0012878937,0.00024686952,0.000043438547,0.00049568206,0.001865728,0.00077113806,0.013063208,0.9396474],"study_design_scores_gemma":[0.018356966,0.009611536,0.018591296,0.029545715,0.01624044,0.0072522904,0.00029884884,0.00086646737,0.003866689,0.002918609,0.8923125,0.00013868556],"about_ca_topic_score_codex":0.0015649727,"about_ca_topic_score_gemma":0.005107021,"teacher_disagreement_score":0.0031386528,"about_ca_system_score_codex":0.0006060896,"about_ca_system_score_gemma":0.0011927809,"threshold_uncertainty_score":0.006253302},"labels":[],"label_agreement":null},{"id":"W2065876746","doi":"10.1053/j.seminoncol.2003.11.036","title":"New frontiers in the treatment of malignant glioma","year":2003,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Loss of heterozygosity; Glioma; CDKN2A; Radiation therapy; Oncology; Chemotherapy; Oligodendroglioma; Neurosurgery; Targeted therapy; Internal medicine; Bioinformatics; Cancer research; Astrocytoma; Gene; Cancer; Surgery; Biology; Genetics; Allele","score_opus":0.04241988482452763,"score_gpt":0.36986062256930724,"score_spread":0.3274407377447796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065876746","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047032034,0.99898964,0.0000865847,0.00027627422,0.00019707743,0.0000022590277,0.0000044533217,0.000003791792,0.00039280794],"genre_scores_gemma":[0.00040743625,0.9986676,0.00015145363,0.00024471004,0.0002622513,0.0000029446614,0.000010717729,9.43983e-7,0.0002520017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996748,0.00008851779,0.000045209083,0.000050008115,0.00011001602,0.000031554464],"domain_scores_gemma":[0.999408,0.00034697808,0.000072476825,0.000017242011,0.000111934976,0.000043295677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012065857,0.0012195946,0.0025364899,0.002956112,0.00037260324,0.0014061313,0.0012917854,0.0015950955,0.0033712124],"category_scores_gemma":[0.0012095574,0.00033989994,0.00086649274,0.0031461318,0.001008837,0.0023315905,0.0008249835,0.0027380604,0.0017817494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017695843,0.00010697306,0.00016814706,0.017259102,0.0001245646,0.0005450321,0.000067477486,0.0006380968,0.0011945731,0.003873447,0.030910777,0.94493484],"study_design_scores_gemma":[0.00008439134,0.00017079951,0.000861104,0.004559584,0.00018999261,0.0021189793,0.00009348613,0.00012984077,0.00035317772,0.0029832497,0.9884299,0.000025521273],"about_ca_topic_score_codex":0.0020670993,"about_ca_topic_score_gemma":0.005238009,"teacher_disagreement_score":0.0033712124,"about_ca_system_score_codex":0.0011712433,"about_ca_system_score_gemma":0.0014799943,"threshold_uncertainty_score":0.011277795},"labels":[],"label_agreement":null},{"id":"W2070471476","doi":"10.1053/j.seminoncol.2005.07.008","title":"Epigenetic Therapy of Cancer With 5-Aza-2′-Deoxycytidine (decitabine)","year":2005,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":197,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Decitabine; Azacitidine; Cancer research; DNA methylation; Medicine; Leukemia; Cancer; Epigenetics; Epigenetic therapy; Pharmacology; Biology; Immunology; Internal medicine; Genetics; Gene; Gene expression","score_opus":0.04006985032835864,"score_gpt":0.39938058844296526,"score_spread":0.3593107381146066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070471476","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007959529,0.995423,0.00078847713,0.00031226585,0.00046308283,0.00001061104,0.000023095534,0.000023112874,0.0021604644],"genre_scores_gemma":[0.005370762,0.9894553,0.00081052096,0.00032922724,0.00021843593,0.000018102335,0.00006384991,0.0000042044035,0.0037296],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99992967,0.000010666462,0.0000069977195,0.000016594344,0.000024257952,0.000011695583],"domain_scores_gemma":[0.999943,0.000024871326,0.000009413219,0.0000033281779,0.000012381386,0.0000069184953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032096988,0.00067338016,0.0011968048,0.000845127,0.00021500495,0.00042287455,0.000913949,0.0007478003,0.0022768767],"category_scores_gemma":[0.0002058723,0.00018185333,0.00028217718,0.00085787405,0.00032304265,0.00038588108,0.00035446708,0.001151348,0.0015904602],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015835429,0.000083886815,0.000120116136,0.0033441717,0.00007347764,0.00032117232,0.000035947214,0.0004006486,0.012899849,0.0026561283,0.017420469,0.96248573],"study_design_scores_gemma":[0.00009131373,0.0002165889,0.001267001,0.00058687985,0.00012965915,0.002393208,0.00003219856,0.0001847359,0.014252826,0.0010854058,0.97974133,0.00001883909],"about_ca_topic_score_codex":0.0011604229,"about_ca_topic_score_gemma":0.003184658,"teacher_disagreement_score":0.0022768767,"about_ca_system_score_codex":0.0006778348,"about_ca_system_score_gemma":0.0003755836,"threshold_uncertainty_score":0.0076168776},"labels":[],"label_agreement":null},{"id":"W2072311991","doi":"10.1053/j.seminoncol.2003.08.020","title":"Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications","year":2003,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Erythropoietin; Medicine; Epoetin alfa; Hypoxia (environmental); Angiogenesis; Vascular endothelial growth factor; Breast cancer; Internal medicine; Cancer; Oncology; Cancer research; VEGF receptors","score_opus":0.048723937167649375,"score_gpt":0.432361008081544,"score_spread":0.3836370709138946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072311991","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001609403,0.99915445,0.0000629441,0.00014767937,0.000052957705,0.0000026489588,0.0000038472017,0.0000023992957,0.00041221583],"genre_scores_gemma":[0.0014877672,0.9977654,0.00017852668,0.00014485908,0.000116328396,0.0000076178026,0.000011050381,7.6334635e-7,0.00028768776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998209,0.000045242432,0.000024477322,0.000029972116,0.00006376793,0.0000157414],"domain_scores_gemma":[0.9996191,0.0002662213,0.000042069856,0.0000075419616,0.00004606426,0.000018937502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009440419,0.00075574947,0.0021345385,0.0011817061,0.00031116803,0.0009259066,0.00093721953,0.0012408178,0.0026290244],"category_scores_gemma":[0.0007660252,0.00021422165,0.00053452625,0.0018180608,0.00050994864,0.00091755606,0.00042507582,0.0016753984,0.0009761289],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003669753,0.00015627193,0.00020512017,0.010747196,0.00017318605,0.00027541618,0.00005082007,0.00030044338,0.0016155022,0.0029849634,0.010932755,0.9721913],"study_design_scores_gemma":[0.00036171067,0.0007130256,0.003446982,0.006018341,0.0007641089,0.004526153,0.00019100809,0.0002811029,0.0025723805,0.0046203556,0.9764639,0.000040958872],"about_ca_topic_score_codex":0.0013304676,"about_ca_topic_score_gemma":0.0029107207,"teacher_disagreement_score":0.0026290244,"about_ca_system_score_codex":0.00064113433,"about_ca_system_score_gemma":0.0010569874,"threshold_uncertainty_score":0.008794904},"labels":[],"label_agreement":null},{"id":"W2072648699","doi":"10.1053/j.seminoncol.2014.04.006","title":"Platelets Effects on Tumor Growth","year":2014,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Intravasation; Platelet; Extravasation; Medicine; Metastasis; Cancer research; Cancer; Cancer cell; Primary tumor; Tumor microenvironment; Tumor cells; Cell biology; Immunology; Pathology; Biology; Internal medicine","score_opus":0.020486402201631504,"score_gpt":0.3599807626362805,"score_spread":0.339494360434649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072648699","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010222679,0.999218,0.000041414904,0.00014188928,0.00013476716,0.0000038139206,0.00001593629,0.0000031929105,0.00033879202],"genre_scores_gemma":[0.0010094896,0.99816716,0.00008169722,0.00016476212,0.00016844366,0.000006864649,0.000025457783,7.3381545e-7,0.00037528574],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998417,0.00002798337,0.000034877317,0.000024645595,0.00005407487,0.000016598835],"domain_scores_gemma":[0.99977213,0.00010458871,0.00005318085,0.0000070807782,0.000044358138,0.000018756875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042827375,0.0010102692,0.0016714839,0.0018122421,0.00019867366,0.0010643059,0.0005321603,0.0010063013,0.0037447782],"category_scores_gemma":[0.0008042633,0.0003780862,0.000539293,0.001810579,0.00036378682,0.0008179714,0.0007826411,0.0015744669,0.00131604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002804857,0.00009203699,0.00030644232,0.029920947,0.00032003297,0.0002528601,0.00004572781,0.00032758657,0.001580911,0.0012669766,0.028671375,0.93693453],"study_design_scores_gemma":[0.0002595049,0.00040588263,0.003078328,0.0123651065,0.0016736164,0.0019637605,0.00011193817,0.00025600163,0.0018828849,0.0020077745,0.97593826,0.000056923574],"about_ca_topic_score_codex":0.0008115821,"about_ca_topic_score_gemma":0.0018529686,"teacher_disagreement_score":0.0037447782,"about_ca_system_score_codex":0.00038727987,"about_ca_system_score_gemma":0.0009440351,"threshold_uncertainty_score":0.012527525},"labels":[],"label_agreement":null},{"id":"W2073922081","doi":"10.1053/j.seminoncol.2008.12.007","title":"Management of Early and Locally Advanced Cervical Cancer","year":2009,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Cervical cancer; Malignancy; Cancer; Primary treatment; Cervical carcinoma; Oncology; Primary cancer; Internal medicine; Intensive care medicine","score_opus":0.037623921247355,"score_gpt":0.4045031393347371,"score_spread":0.3668792180873821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073922081","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005992723,0.99947387,0.00003895978,0.0000773923,0.00006930934,0.000002315243,0.0000053457397,0.0000018612106,0.00027105518],"genre_scores_gemma":[0.00074343785,0.9986998,0.000114073344,0.00015455215,0.00009743894,0.0000033649712,0.0000151132635,6.6268296e-7,0.00017159176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997446,0.000063769694,0.00004561698,0.00004118184,0.00008316081,0.00002155893],"domain_scores_gemma":[0.99963546,0.00022241037,0.00006368816,0.0000069460602,0.00005219611,0.000019364568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006025333,0.00079789467,0.0017649048,0.0019463013,0.00023455566,0.00085125654,0.0012090425,0.0009227124,0.0026813454],"category_scores_gemma":[0.0012297104,0.000303252,0.0006760281,0.0015776791,0.00048037161,0.0010146855,0.00055577705,0.001364874,0.0008692188],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008150867,0.000049446226,0.00024942696,0.029740477,0.0001350238,0.00027671916,0.00004091218,0.00030071143,0.00047076907,0.00062817766,0.015878754,0.95214814],"study_design_scores_gemma":[0.00012685783,0.00029963782,0.0039426037,0.0358906,0.0009979202,0.0057235686,0.00024705732,0.00024025496,0.0005801218,0.0016375242,0.9502664,0.000047464557],"about_ca_topic_score_codex":0.0021675846,"about_ca_topic_score_gemma":0.0055577545,"teacher_disagreement_score":0.0026813454,"about_ca_system_score_codex":0.0006425382,"about_ca_system_score_gemma":0.0009814752,"threshold_uncertainty_score":0.008969963},"labels":[],"label_agreement":null},{"id":"W2074340276","doi":"10.1053/sonc.2003.50042","title":"Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulimenia","year":2003,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Proteoglycans and glycosaminoglycans research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Hyaluronan synthase; Extracellular matrix; Hyaluronic acid; Immune system; Multiple myeloma; Waldenstrom macroglobulinemia; Extracellular; Cancer research; Molecular biology; Cell biology; Medicine; Biology; Pathology; Immunology; Lymphoma; Genetics","score_opus":0.005451976096725701,"score_gpt":0.2586122874170537,"score_spread":0.253160311320328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074340276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989795,0.00029091217,0.00010493813,0.000049453534,0.00000824672,0.0000037048824,0.00007335272,0.000009327727,0.00048051053],"genre_scores_gemma":[0.99976677,0.00006471485,0.000048043443,0.000011516008,0.0000115597795,0.0000026298949,0.000038940365,0.0000014659097,0.000054327134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997906,0.000039576636,0.00003206799,0.00003545114,0.00004870954,0.000053595315],"domain_scores_gemma":[0.9993716,0.00025406582,0.0001706329,0.000026323187,0.000055058048,0.00012245815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020454318,0.00042543132,0.0003574181,0.0023336145,0.00045459706,0.0004804708,0.0002617879,0.0005292615,0.0012561956],"category_scores_gemma":[0.0020007647,0.00023244068,0.00021774945,0.0011214948,0.0003795209,0.00029237432,0.00022785901,0.0002975891,0.00017294352],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070406834,0.000044470722,0.9406664,0.00004013497,0.000051752653,0.029666644,0.00047838647,0.00013580982,0.023237199,0.00014600773,0.00018995094,0.004639262],"study_design_scores_gemma":[0.000021885242,0.00015105226,0.94869554,0.000010076562,0.00010867421,0.045287248,0.00040298235,0.00063493196,0.0040023224,0.00022638205,0.00044587752,0.000012964833],"about_ca_topic_score_codex":0.001149508,"about_ca_topic_score_gemma":0.00062203483,"teacher_disagreement_score":0.0023336145,"about_ca_system_score_codex":0.00020529954,"about_ca_system_score_gemma":0.00020364433,"threshold_uncertainty_score":0.0042024255},"labels":[],"label_agreement":null},{"id":"W2074609728","doi":"10.1053/j.seminoncol.2007.03.008","title":"Local Management of Adult Soft Tissue Sarcomas","year":2007,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Radiation therapy; Sarcoma; Soft tissue; Adjuvant radiotherapy; Trunk; Surgery; Soft tissue sarcoma; Adjuvant; Adjuvant therapy; Radiology; Oncology; Chemotherapy; Pathology","score_opus":0.04790951265337286,"score_gpt":0.4122803651611181,"score_spread":0.36437085250774526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074609728","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018713315,0.9990702,0.00012497645,0.00007444729,0.00007015152,0.0000030344684,0.000005962429,0.0000054562065,0.0004586302],"genre_scores_gemma":[0.0018840862,0.9970901,0.00022796704,0.00020855888,0.00014183471,0.0000053661975,0.000025112286,0.000001985711,0.00041501282],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997967,0.00004627094,0.00003402905,0.00003768275,0.000066799395,0.00001856566],"domain_scores_gemma":[0.9996947,0.00016823613,0.00006394354,0.000008784588,0.000043732143,0.000020537678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045327534,0.00072106544,0.0016163144,0.0017049684,0.0002281677,0.0007277154,0.001045003,0.00070163264,0.002634494],"category_scores_gemma":[0.00072932953,0.00025804332,0.0005687325,0.001448023,0.00045693616,0.0009741914,0.00050019403,0.0011067874,0.0011472321],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059431335,0.00005332992,0.00022454621,0.014501839,0.000087680164,0.00052256184,0.000037092144,0.00040286206,0.00090810744,0.0004670072,0.012389385,0.9703461],"study_design_scores_gemma":[0.00013735385,0.00050910213,0.004839194,0.018921407,0.00084932084,0.022079855,0.00025204066,0.00037807217,0.0016187474,0.0015415462,0.9488139,0.00005946597],"about_ca_topic_score_codex":0.00086887873,"about_ca_topic_score_gemma":0.0028868471,"teacher_disagreement_score":0.002634494,"about_ca_system_score_codex":0.00042810765,"about_ca_system_score_gemma":0.000526513,"threshold_uncertainty_score":0.008813262},"labels":[],"label_agreement":null},{"id":"W2078136306","doi":"10.1053/j.seminoncol.2004.07.029","title":"Perspectives on the future of bisphosphonate use in breast cancer patients","year":2004,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Clinical trial; Bisphosphonate; Stage (stratigraphy); Oncology; Disease; Cancer; Adjuvant therapy; Internal medicine; Bone disease; Surgery; Intensive care medicine; Osteoporosis","score_opus":0.026847680153339094,"score_gpt":0.37426792429964384,"score_spread":0.34742024414630474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078136306","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005326611,0.99803144,0.000025422687,0.0011745896,0.0002565975,9.391815e-7,0.0000069059874,0.0000022032125,0.00044860103],"genre_scores_gemma":[0.0004496784,0.99841344,0.00006321384,0.00057866774,0.00026793202,0.0000021652443,0.000008912484,3.5469387e-7,0.0002155824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99958915,0.00012691894,0.000061836894,0.000052270996,0.0001324307,0.000037462643],"domain_scores_gemma":[0.99900335,0.00056414405,0.00013420025,0.000013775315,0.00021989695,0.00006471109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015721238,0.0007153197,0.002281269,0.0019474012,0.00039039744,0.0018974888,0.0010060526,0.0024956474,0.0060522505],"category_scores_gemma":[0.001766152,0.0003145276,0.00080899964,0.0028139306,0.00058387895,0.0019012404,0.000632774,0.0024732994,0.0018115073],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028113375,0.000111872505,0.0006772468,0.018030405,0.00021622823,0.0006304242,0.00010040359,0.00040628103,0.00070547115,0.004586127,0.054017022,0.9202374],"study_design_scores_gemma":[0.00012418252,0.00019823448,0.0024576597,0.014145956,0.00046611126,0.0022645113,0.0003119808,0.00020198744,0.00021714317,0.0035394616,0.9760381,0.00003477914],"about_ca_topic_score_codex":0.0035231723,"about_ca_topic_score_gemma":0.011826676,"teacher_disagreement_score":0.0060522505,"about_ca_system_score_codex":0.001405383,"about_ca_system_score_gemma":0.0023683074,"threshold_uncertainty_score":0.020246804},"labels":[],"label_agreement":null},{"id":"W2087324461","doi":"10.1053/j.seminoncol.2014.04.007","title":"Pharmacological Regulation of Platelet Factors That Influence Tumor Angiogenesis","year":2014,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Angiogenesis; Medicine; Platelet; Metastasis; Hemostasis; Cancer research; Neovascularization; Mechanism (biology); Pathological; Cancer; Immunology; Pharmacology; Internal medicine","score_opus":0.03620789227325197,"score_gpt":0.3634344828822936,"score_spread":0.3272265906090416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087324461","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005763478,0.996619,0.00061324384,0.00031443988,0.000293666,0.000013234665,0.000031760545,0.000018349014,0.0015199629],"genre_scores_gemma":[0.00348389,0.99413764,0.00059323694,0.00032800765,0.00028746764,0.000026268364,0.00006978426,0.0000038598205,0.0010698495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998665,0.000019732952,0.00001657612,0.000021983677,0.000053979395,0.00002118784],"domain_scores_gemma":[0.99988747,0.000050656745,0.000019965844,0.000005709437,0.000021559606,0.000014512957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004800981,0.000905657,0.0010660564,0.0010735088,0.00019188615,0.0008645444,0.0008057058,0.0009378626,0.0016178994],"category_scores_gemma":[0.00045829412,0.0002994915,0.0004238538,0.0012022377,0.00049141893,0.0007151322,0.00051232235,0.0019752185,0.0012497439],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024109955,0.00017953002,0.00025293705,0.009087395,0.0001275444,0.00046309683,0.000044504697,0.00067521964,0.01588899,0.005748674,0.026839225,0.9404518],"study_design_scores_gemma":[0.00014003931,0.00030884266,0.0015437768,0.0012195444,0.00025803884,0.0018446799,0.00004414861,0.0003269884,0.008672312,0.0032387632,0.9823631,0.00003973369],"about_ca_topic_score_codex":0.00044595983,"about_ca_topic_score_gemma":0.0007170793,"teacher_disagreement_score":0.0016178994,"about_ca_system_score_codex":0.0004945851,"about_ca_system_score_gemma":0.0004953676,"threshold_uncertainty_score":0.0054124594},"labels":[],"label_agreement":null},{"id":"W2089410776","doi":"10.1016/s0093-7754(01)90035-1","title":"Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials","year":2001,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Québec Metro High Tech Park (Canada)","funders":"","keywords":"Medicine; Angiogenesis; Vascular endothelial growth factor; In vivo; Lewis lung carcinoma; Pharmacology; Matrigel; Neovascularization; Blood vessel; Thalidomide; Basic fibroblast growth factor; Cancer research; Bone marrow; Matrix metalloproteinase inhibitor; Matrix metalloproteinase; Cancer; Immunology; Internal medicine; Growth factor; Multiple myeloma; Receptor; Biology; VEGF receptors; Metastasis","score_opus":0.24415275304753292,"score_gpt":0.5670275841619712,"score_spread":0.32287483111443827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089410776","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001577138,0.9953382,0.0004461708,0.00042196136,0.00021536238,0.000055161563,0.0000775735,0.000027629154,0.001840753],"genre_scores_gemma":[0.005685453,0.99084187,0.0009958022,0.000677027,0.00012457141,0.000071647926,0.0002013976,0.000005063821,0.0013970889],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998266,0.0000397457,0.000021909715,0.000027890499,0.000061002454,0.00002278276],"domain_scores_gemma":[0.99959356,0.0002111873,0.00006751168,0.000012206398,0.000059271973,0.000056308796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016198864,0.0008809957,0.0026266624,0.0010616957,0.00026608488,0.0009747852,0.0009734715,0.0010488294,0.0034469066],"category_scores_gemma":[0.0009035798,0.00022100237,0.00061821414,0.0018682681,0.0003470021,0.0008454609,0.0003500351,0.0015265638,0.0014534433],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010014417,0.00027391216,0.0002813944,0.009216054,0.00016401838,0.00025894112,0.00004064943,0.00042954728,0.0035052828,0.00096546434,0.016036374,0.96782684],"study_design_scores_gemma":[0.0031815525,0.005529213,0.004013382,0.0060885353,0.0015692794,0.0039117574,0.00014027217,0.0005639173,0.006724888,0.0019560987,0.96625715,0.00006391882],"about_ca_topic_score_codex":0.0007907602,"about_ca_topic_score_gemma":0.0023715813,"teacher_disagreement_score":0.0034469066,"about_ca_system_score_codex":0.0005117079,"about_ca_system_score_gemma":0.0012385577,"threshold_uncertainty_score":0.011531055},"labels":[],"label_agreement":null},{"id":"W2089445137","doi":"10.1053/j.seminoncol.2004.11.013","title":"Palliative radiation therapy","year":2005,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Radiosurgery; Radiation therapy; Palliative care; Cancer; Lung cancer; Population; Disease; Stereotactic radiation therapy; Surgery; Performance status; Oncology; Internal medicine","score_opus":0.09286949844267094,"score_gpt":0.4563326392391604,"score_spread":0.36346314079648945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089445137","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020540023,0.9945589,0.00033849434,0.00022237883,0.0004368332,0.000009820829,0.000022780127,0.00001662255,0.004188712],"genre_scores_gemma":[0.002927333,0.9920557,0.00047970042,0.0006491324,0.00042197292,0.00001772176,0.00008011684,0.0000043438235,0.0033638831],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998938,0.000028455195,0.000014168636,0.00002422772,0.000028097973,0.0000112194575],"domain_scores_gemma":[0.9998604,0.00006393743,0.000029094426,0.000008241722,0.000024352348,0.000013990379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002616327,0.00085663906,0.0013550984,0.001377974,0.00028144044,0.00055768574,0.0006192954,0.0006126699,0.008735324],"category_scores_gemma":[0.00063456286,0.0002071212,0.00038211956,0.0014185287,0.0003643208,0.00079711684,0.0006267796,0.001123611,0.0031145182],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004751885,0.000027332107,0.00009734477,0.009755928,0.00005358532,0.00023599363,0.000031147454,0.00030882482,0.0009457316,0.0011548006,0.036646854,0.9506949],"study_design_scores_gemma":[0.00004334645,0.00011713345,0.000977722,0.005346078,0.00018922049,0.0059678387,0.000037500384,0.00010394852,0.00064149965,0.001369677,0.98519045,0.000015671834],"about_ca_topic_score_codex":0.00050277787,"about_ca_topic_score_gemma":0.001812777,"teacher_disagreement_score":0.008735324,"about_ca_system_score_codex":0.00044901273,"about_ca_system_score_gemma":0.0006253312,"threshold_uncertainty_score":0.029222608},"labels":[],"label_agreement":null},{"id":"W2089735828","doi":"10.1053/j.seminoncol.2011.01.018","title":"Differential Properties of Current Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors","year":2011,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Novartis Pharmaceuticals Canada","keywords":"Sunitinib; Medicine; Regorafenib; Dasatinib; GiST; Imatinib; Nilotinib; Tyrosine kinase; Sorafenib; Tyrosine-kinase inhibitor; Imatinib mesylate; Pazopanib; Oncology; Internal medicine; Cancer research; Pharmacology; Cancer; Stromal cell; Colorectal cancer; Hepatocellular carcinoma; Receptor","score_opus":0.10511166489116196,"score_gpt":0.3827375051002066,"score_spread":0.2776258402090446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089735828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035854464,0.9987263,0.00012924055,0.0001354458,0.00006431365,0.0000031210711,0.000019841054,0.0000048797115,0.000558233],"genre_scores_gemma":[0.0020286152,0.99696475,0.00021222926,0.00020098292,0.00011877505,0.0000059208373,0.000042872856,0.000001663741,0.0004241213],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997969,0.000027850705,0.000038737002,0.00004031058,0.00007389833,0.000022261087],"domain_scores_gemma":[0.99957234,0.00024149023,0.000078418714,0.000010099085,0.00007474257,0.000023000794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075845496,0.0008577846,0.0018204075,0.001773567,0.00016887853,0.0010772824,0.00080068497,0.00075779686,0.0019410648],"category_scores_gemma":[0.00085653627,0.00029514756,0.0007125041,0.0020136072,0.00039962033,0.0012458159,0.00047452212,0.0016069555,0.0009526432],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020241566,0.00007131261,0.0003516848,0.010013984,0.00015103462,0.000306826,0.000046433175,0.00050859683,0.0031935906,0.0014048072,0.010295826,0.9734535],"study_design_scores_gemma":[0.00018476932,0.0005354805,0.003646897,0.003812427,0.0009091915,0.004789237,0.00009663357,0.00042452445,0.0043136026,0.0018451214,0.9793879,0.000054142867],"about_ca_topic_score_codex":0.00063366,"about_ca_topic_score_gemma":0.001861979,"teacher_disagreement_score":0.0019410648,"about_ca_system_score_codex":0.0005739015,"about_ca_system_score_gemma":0.0005232258,"threshold_uncertainty_score":0.006493449},"labels":[],"label_agreement":null},{"id":"W2092841476","doi":"10.1053/j.seminoncol.2003.12.015","title":"Antiangiogenic drugs and current strategies for the treatment of lung cancer","year":2004,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Angiogenesis; Cancer; Vascular endothelial growth factor; Chemotherapy; Oncology; Bevacizumab; Clinical trial; Mesothelioma; Cancer research; Immunology; Internal medicine; Pathology; VEGF receptors","score_opus":0.03280033381728383,"score_gpt":0.40697332122602137,"score_spread":0.37417298740873756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092841476","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008001806,0.99800104,0.00022965984,0.0004365102,0.00041945736,0.000004771996,0.000008713302,0.000009978699,0.0008098202],"genre_scores_gemma":[0.0005494723,0.99717736,0.00036423674,0.0003702144,0.00045819083,0.0000107101905,0.0000256302,0.0000019415122,0.0010421907],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997553,0.000044767366,0.000026835032,0.000038384864,0.00010565119,0.00002911063],"domain_scores_gemma":[0.9994973,0.00026518042,0.000049816565,0.000015871967,0.0001089077,0.000062981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011545632,0.0012514079,0.0019996748,0.0020428337,0.00043841987,0.0013584256,0.0015665344,0.0019470572,0.004497534],"category_scores_gemma":[0.00091886095,0.0003815372,0.0005665408,0.002378799,0.0010234748,0.0021321855,0.00059508113,0.0037417482,0.0031069785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022136906,0.0001485493,0.00013842582,0.0051608137,0.00007408856,0.0003145125,0.00003968418,0.0005992664,0.0021587606,0.00580185,0.052927468,0.93241525],"study_design_scores_gemma":[0.00008824629,0.00015960241,0.00056696864,0.0011661376,0.00010786106,0.0015544092,0.00004098413,0.00016946316,0.00058858725,0.0029786918,0.9925604,0.000018697807],"about_ca_topic_score_codex":0.0012660247,"about_ca_topic_score_gemma":0.0031410079,"teacher_disagreement_score":0.004497534,"about_ca_system_score_codex":0.0010163201,"about_ca_system_score_gemma":0.0010902165,"threshold_uncertainty_score":0.015045702},"labels":[],"label_agreement":null},{"id":"W2093944201","doi":"10.1053/j.seminoncol.2013.05.011","title":"Selected Toxicities of Targeted Therapies: Presentation and Management","year":2013,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Targeted therapy; Intensive care medicine; Dosing; Toxicity; Renal cell carcinoma; Disease; Radiation therapy; Intervention (counseling); Oncology; Cancer; Internal medicine; Psychiatry","score_opus":0.014273307442966442,"score_gpt":0.2872275127491344,"score_spread":0.27295420530616793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093944201","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7131876,0.15688132,0.024479797,0.011088313,0.0005474916,0.00092024065,0.001422704,0.00032644364,0.09114609],"genre_scores_gemma":[0.9118173,0.0658794,0.00807583,0.0026538938,0.0019152375,0.0002153387,0.0012490799,0.000096504846,0.008097366],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997292,0.00005986861,0.000053012936,0.00002529418,0.00007002608,0.00006248011],"domain_scores_gemma":[0.99954873,0.00011296229,0.00015570698,0.000014374068,0.00009663079,0.000071565155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004180827,0.0005174976,0.00058799953,0.0009991251,0.000390996,0.0006981116,0.0004342466,0.00060729,0.0015525734],"category_scores_gemma":[0.0014940731,0.00015497718,0.00049054023,0.001053499,0.00019858843,0.00063518126,0.00037465824,0.0008071678,0.00037644582],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002098336,0.0006817365,0.29676396,0.0010606315,0.00022078249,0.09909878,0.0006964961,0.004125541,0.009257011,0.0046890713,0.016913766,0.56439394],"study_design_scores_gemma":[0.0002611377,0.0021970337,0.32464305,0.00097399106,0.0004090321,0.58743614,0.0009884518,0.0048948987,0.007379273,0.00560799,0.06511901,0.00009005758],"about_ca_topic_score_codex":0.000596714,"about_ca_topic_score_gemma":0.0012803783,"teacher_disagreement_score":0.0015525734,"about_ca_system_score_codex":0.0009963665,"about_ca_system_score_gemma":0.0005632033,"threshold_uncertainty_score":0.0072291493},"labels":[],"label_agreement":null},{"id":"W2097235491","doi":"10.1016/s0093-7754(01)90226-x","title":"Extending preclinical models of skeletal manifestations of malignancy to the clinical setting","year":2001,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Osteomalacia; Hypophosphatemia; Malignancy; Prostate cancer; Osteolysis; Calcitriol; Osteopenia; Cancer; Parathyroid hormone; Internal medicine; Oncology; Cancer research; Pathology; Vitamin D and neurology; Osteoporosis; Bone mineral; Surgery; Calcium","score_opus":0.19191769477285311,"score_gpt":0.5339223273840648,"score_spread":0.3420046326112116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097235491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032703803,0.9954057,0.0010372337,0.000581823,0.00027800334,0.000019531431,0.000026821552,0.000015806405,0.0023080325],"genre_scores_gemma":[0.0013502785,0.99669707,0.0008428185,0.00034711484,0.00013162874,0.000020771884,0.000041022333,0.0000020601403,0.0005672061],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972075,0.00007292701,0.000032540567,0.000048374364,0.00009819234,0.000027235765],"domain_scores_gemma":[0.9992555,0.00049177423,0.00006426009,0.00003963861,0.000105982755,0.00004290388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012971578,0.0016075186,0.002374965,0.0022930282,0.00032462986,0.0014301676,0.0016455005,0.001995227,0.0028620565],"category_scores_gemma":[0.00090345676,0.00043194313,0.0008175241,0.0016638244,0.0010338259,0.0018629975,0.00082122267,0.003363331,0.0017546722],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017553568,0.0004348923,0.00035284442,0.021228533,0.00011841778,0.0007598404,0.0001082228,0.0013011424,0.019142512,0.010572384,0.021901254,0.92390436],"study_design_scores_gemma":[0.00010459312,0.0004761815,0.0016288047,0.0055521876,0.00023125623,0.0030870293,0.00014707238,0.0002686672,0.005483809,0.00876004,0.97421455,0.00004585544],"about_ca_topic_score_codex":0.0014931144,"about_ca_topic_score_gemma":0.003935751,"teacher_disagreement_score":0.0028620565,"about_ca_system_score_codex":0.000863865,"about_ca_system_score_gemma":0.0015960103,"threshold_uncertainty_score":0.009574592},"labels":[],"label_agreement":null},{"id":"W2100143077","doi":"10.1053/j.seminoncol.2005.02.013","title":"Redefining Bronchioloalveolar Carcinoma","year":2005,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Histopathology; Adenocarcinoma; Lung cancer; Pathology; Carcinoma; Cancer; Natural history; Lung; Internal medicine","score_opus":0.04757776916274788,"score_gpt":0.44223082909283284,"score_spread":0.394653059930085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100143077","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016934797,0.9980856,0.00013935684,0.00037564177,0.00039967988,0.000004581793,0.000009335934,0.000007336138,0.0008089906],"genre_scores_gemma":[0.0017754973,0.99529546,0.00028618847,0.00081251183,0.00044511637,0.000008961298,0.000026605157,0.000002540938,0.0013470962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998264,0.00003668668,0.00003009728,0.000031069492,0.00005424754,0.00002149885],"domain_scores_gemma":[0.9997305,0.00013746305,0.00004861287,0.0000121867015,0.000052531577,0.000018655053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000661794,0.0007305514,0.0015764282,0.0016928649,0.00024474962,0.0006897197,0.0008561437,0.0011552233,0.0031544918],"category_scores_gemma":[0.0008560047,0.00030684512,0.00045353643,0.001321432,0.00053497753,0.0012692714,0.00055921846,0.0015938514,0.0016013645],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008540155,0.000044734268,0.0001387106,0.009745653,0.000092526134,0.00040593045,0.00003819718,0.0003125418,0.0021311636,0.0015755844,0.030515675,0.95491385],"study_design_scores_gemma":[0.000070502705,0.00013608688,0.00090566993,0.0028210392,0.00022694876,0.0026949933,0.000039989136,0.00009815599,0.0013714893,0.0009030128,0.99071735,0.000014751305],"about_ca_topic_score_codex":0.0008598922,"about_ca_topic_score_gemma":0.0030127945,"teacher_disagreement_score":0.0031544918,"about_ca_system_score_codex":0.0006320206,"about_ca_system_score_gemma":0.0007700756,"threshold_uncertainty_score":0.010552824},"labels":[],"label_agreement":null},{"id":"W2107019084","doi":"10.1053/j.seminoncol.2011.05.009","title":"Treatment of Metastatic Colorectal Cancer","year":2011,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alberta Heritage Foundation for Medical Research","keywords":"Medicine; Colorectal cancer; Oncology; Chemotherapy; Internal medicine; Fluorouracil; Bevacizumab; Monoclonal antibody; Cancer; Antibody; Immunology","score_opus":0.0568908873638325,"score_gpt":0.36742412640277217,"score_spread":0.31053323903893965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107019084","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29019362,0.4891772,0.0025238886,0.019612212,0.0031741722,0.00030844499,0.001035382,0.00015296914,0.19382223],"genre_scores_gemma":[0.8207711,0.13318077,0.0016426365,0.005170262,0.002430933,0.00017967387,0.0010326633,0.00002698646,0.03556492],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999137,0.000032962074,0.000004596869,0.000009428251,0.000021309863,0.000017955264],"domain_scores_gemma":[0.99991536,0.000019359797,0.000018713888,0.0000071211202,0.000010678727,0.000028754854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018660152,0.00014598544,0.00023402556,0.00037448382,0.00024733684,0.00025645862,0.00016754742,0.00022687262,0.00669842],"category_scores_gemma":[0.00044878744,0.000044739914,0.00038127627,0.00043223283,0.00013858973,0.00018240782,0.00022131551,0.00041650402,0.000989099],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026741475,0.0005091956,0.0072815027,0.0020250485,0.00016881246,0.0013893407,0.00010767388,0.00042198887,0.010029006,0.0025776434,0.0290774,0.9437382],"study_design_scores_gemma":[0.0020769904,0.014031879,0.13002357,0.0015572705,0.0005787325,0.0155204395,0.00025838963,0.00056180794,0.011980597,0.0033287085,0.82004905,0.0000325544],"about_ca_topic_score_codex":0.00070381415,"about_ca_topic_score_gemma":0.00210948,"teacher_disagreement_score":0.00669842,"about_ca_system_score_codex":0.00035645833,"about_ca_system_score_gemma":0.00029655025,"threshold_uncertainty_score":0.022408485},"labels":[],"label_agreement":null},{"id":"W2111959414","doi":"10.1016/s0093-7754(01)90215-5","title":"The effect of hemoglobin level on radiotherapy outcomes: The Canadian experience","year":2001,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Blood transfusion and management","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Radiation therapy; Univariate analysis; Anemia; Multivariate analysis; Internal medicine; Retrospective cohort study; Blood transfusion; Hemoglobin; Carcinoma; Stage (stratigraphy); Regimen; Surgery; Gastroenterology","score_opus":0.02303835331426013,"score_gpt":0.3452024190128664,"score_spread":0.3221640656986063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111959414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96679294,0.0046846396,0.0001631193,0.007083532,0.0001187052,0.000055757326,0.0015684845,0.0000148920135,0.019517925],"genre_scores_gemma":[0.99082935,0.005050482,0.00030326482,0.0007333122,0.000065947446,0.000019273883,0.0005889279,0.000025599993,0.0023837925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799937,0.0002354739,0.00007809381,0.00014116253,0.0009480255,0.0005978452],"domain_scores_gemma":[0.994306,0.00081732526,0.0006565411,0.00013524233,0.0020901468,0.001994722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019441118,0.0003731359,0.00051556464,0.0009084598,0.0035484536,0.0014452147,0.0012688714,0.000824122,0.00334179],"category_scores_gemma":[0.007529643,0.0002631796,0.0005556025,0.0043754037,0.0014038627,0.00047858982,0.00074707234,0.0012663328,0.00025808046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011404804,0.00053202163,0.8967906,0.00014039813,0.00017323253,0.0010192622,0.005118022,0.0006845011,0.00035286188,0.0011900825,0.01655647,0.07630203],"study_design_scores_gemma":[0.00008259126,0.00030416806,0.98212665,0.00013037195,0.00012489129,0.0007088463,0.0039164606,0.00024377764,0.00017089903,0.00017251245,0.011944417,0.00007438358],"about_ca_topic_score_codex":0.9852071,"about_ca_topic_score_gemma":0.9937936,"teacher_disagreement_score":0.057041805,"about_ca_system_score_codex":0.057041805,"about_ca_system_score_gemma":0.058268815,"threshold_uncertainty_score":0.4138692},"labels":[],"label_agreement":null},{"id":"W2112324274","doi":"10.1053/j.seminoncol.2004.07.019","title":"Optimizing treatment of HER2-positive metastatic breast cancer","year":2004,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Trastuzumab; Tolerability; Metastatic breast cancer; Breast cancer; Dosing; Oncology; Internal medicine; Regimen; Adverse effect; Clinical trial; Cancer","score_opus":0.044490724554963196,"score_gpt":0.42812279568189776,"score_spread":0.38363207112693454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112324274","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7772238,0.118045665,0.034811314,0.019354643,0.0007592545,0.00023029672,0.00046052012,0.0004538431,0.04866064],"genre_scores_gemma":[0.9561371,0.02506407,0.010956598,0.0016294005,0.00047782916,0.000098947574,0.00023756443,0.00007039409,0.0053281505],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998591,0.00005207909,0.000006951571,0.000016036907,0.000038069404,0.000027778427],"domain_scores_gemma":[0.9999249,0.000026664848,0.000019294972,0.0000046896444,0.000012273721,0.000012145928],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002611913,0.0002449151,0.000373822,0.00018235546,0.00016129322,0.0003929377,0.00025757408,0.00025727466,0.0025200944],"category_scores_gemma":[0.000612686,0.000074919204,0.00020326178,0.00018647773,0.00009579481,0.0002677331,0.00017044222,0.0005198457,0.0003131617],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019364469,0.0010320217,0.009204524,0.0005035739,0.00015437492,0.0002763376,0.00013767864,0.012583935,0.081212245,0.0030884277,0.014240591,0.8756298],"study_design_scores_gemma":[0.0025070002,0.016408509,0.19224523,0.0008568234,0.0021150054,0.008113044,0.0013178114,0.06118818,0.2558658,0.02708503,0.43218634,0.00011135748],"about_ca_topic_score_codex":0.0009059069,"about_ca_topic_score_gemma":0.0023194498,"teacher_disagreement_score":0.0025200944,"about_ca_system_score_codex":0.00045599285,"about_ca_system_score_gemma":0.00044537443,"threshold_uncertainty_score":0.008430541},"labels":[],"label_agreement":null},{"id":"W2113901864","doi":"10.1053/j.seminoncol.2005.04.019","title":"Current Management of Anal Canal Cancer","year":2005,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Colorectal and Anal Carcinomas","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Anal cancer; Capecitabine; Irinotecan; Radiation therapy; Oxaliplatin; Anal canal; Oncology; Mitomycin C; Surgery; Chemoradiotherapy; Fluorouracil; Chemotherapy; Internal medicine; Cancer; Colorectal cancer; Rectum","score_opus":0.07361723804546028,"score_gpt":0.4536214864930432,"score_spread":0.3800042484475829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113901864","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008526451,0.999038,0.000067724875,0.00027092692,0.00013073311,0.000001958905,0.000006755745,0.0000045483926,0.00039415515],"genre_scores_gemma":[0.0006456662,0.9984995,0.00014075807,0.00024892317,0.00020802891,0.0000026525292,0.00002130161,8.2310186e-7,0.00023235717],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996476,0.00007791375,0.00006696291,0.000054670007,0.00012276635,0.00003007285],"domain_scores_gemma":[0.99935406,0.0003270084,0.00012601167,0.000013200211,0.00012795652,0.000051745817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090748747,0.0008645007,0.0021618702,0.0027085452,0.00030079123,0.0012411736,0.0012009963,0.0011111695,0.0031987303],"category_scores_gemma":[0.0015735166,0.00031691726,0.00059799163,0.0027417566,0.0005718133,0.0016699114,0.0006884476,0.0013623422,0.0012699164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076636126,0.000039277304,0.0005307773,0.016731232,0.00010503646,0.00044709342,0.000046024645,0.00027791245,0.00035413651,0.00074346847,0.02317886,0.9574695],"study_design_scores_gemma":[0.000071326176,0.00020202927,0.0044600875,0.024870321,0.0007583366,0.006853275,0.00029462244,0.00022658573,0.0003640406,0.0017724565,0.96008176,0.000045047796],"about_ca_topic_score_codex":0.001904033,"about_ca_topic_score_gemma":0.0055568796,"teacher_disagreement_score":0.0031987303,"about_ca_system_score_codex":0.00082172244,"about_ca_system_score_gemma":0.0013607979,"threshold_uncertainty_score":0.0107008815},"labels":[],"label_agreement":null},{"id":"W2114829356","doi":"10.1053/j.seminoncol.2009.06.006","title":"Small Round Cell Sarcomas","year":2009,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Sarcoma; Chemotherapy; Radiation therapy; Chromosomal translocation; Lymphoma; Leukemia; Clear-cell sarcoma; Cancer; Oncology; Pathology; Cancer research; Internal medicine; Biology; Genetics","score_opus":0.08633677207263338,"score_gpt":0.38638368529394096,"score_spread":0.3000469132213076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114829356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032000625,0.9970611,0.00025019082,0.00025295297,0.0003201082,0.0000075745943,0.000022432789,0.000015051387,0.0017505389],"genre_scores_gemma":[0.002759593,0.9947397,0.00028364148,0.0003054878,0.0003034952,0.000008042071,0.000055000677,0.000002575951,0.0015424285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988365,0.000015557425,0.000022789014,0.000023151864,0.000040458628,0.000014403808],"domain_scores_gemma":[0.99977416,0.000097510936,0.000054641896,0.000011037415,0.00003989597,0.000022787737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027842805,0.00081767485,0.0011153101,0.002646834,0.00019876877,0.00062192074,0.00054281764,0.00052666175,0.0038258755],"category_scores_gemma":[0.00062981923,0.00026804625,0.00032795334,0.0023061223,0.00047506843,0.0012797583,0.0006206213,0.0008250995,0.0017305574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004567349,0.000023684837,0.00020089035,0.008093211,0.000051773997,0.000677452,0.000029672332,0.00031827833,0.0018310621,0.0009073129,0.02792334,0.95989776],"study_design_scores_gemma":[0.000028371634,0.00008648714,0.0011437407,0.0027588673,0.00022088761,0.009612235,0.000060531635,0.00011638528,0.0010684673,0.0010371635,0.98384583,0.00002113849],"about_ca_topic_score_codex":0.00078380725,"about_ca_topic_score_gemma":0.0029365038,"teacher_disagreement_score":0.0038258755,"about_ca_system_score_codex":0.0005158232,"about_ca_system_score_gemma":0.0008183464,"threshold_uncertainty_score":0.012798846},"labels":[],"label_agreement":null},{"id":"W2116041676","doi":"10.1053/j.seminoncol.2009.07.007","title":"The Adolescence of Young Adult Oncology","year":2009,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Subspecialty; Oncofertility; Medicine; Oncology; Population; Medical education; MEDLINE; Family medicine; Internal medicine; Public relations; Fertility preservation; Political science; Fertility","score_opus":0.018370180210441577,"score_gpt":0.35815608219071166,"score_spread":0.3397859019802701,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116041676","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7329021,0.041944183,0.00038941228,0.087465055,0.0021517442,0.000084653315,0.00042332508,0.00003604689,0.13460353],"genre_scores_gemma":[0.97494227,0.013887208,0.00011670576,0.0032927934,0.00020753172,0.00004154856,0.00009242916,0.000013985838,0.007405564],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99937385,0.00023332283,0.000025382315,0.000030167148,0.00006796962,0.00026931876],"domain_scores_gemma":[0.9977436,0.00051714433,0.00029422095,0.000038371978,0.00025693432,0.0011497003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013848,0.00013421995,0.00027428727,0.00081583345,0.004189179,0.0040488965,0.00028939696,0.00093638676,0.003921855],"category_scores_gemma":[0.004160527,0.00021453868,0.00017982058,0.0007848866,0.0015655883,0.0024194943,0.0024014865,0.0018585507,0.0003098108],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013770259,0.0006236748,0.38247973,0.00039423959,0.000028175933,0.0049148286,0.32815433,0.000117558935,0.0011091713,0.065563254,0.06700057,0.14947678],"study_design_scores_gemma":[0.000013372434,0.00011256086,0.26891145,0.001136017,0.000025691694,0.0021956384,0.41050008,0.00006454635,0.00032935926,0.0071319924,0.30955356,0.000025669626],"about_ca_topic_score_codex":0.020211667,"about_ca_topic_score_gemma":0.06850345,"teacher_disagreement_score":0.020211667,"about_ca_system_score_codex":0.0024275295,"about_ca_system_score_gemma":0.00639083,"threshold_uncertainty_score":0.040188015},"labels":[],"label_agreement":null},{"id":"W2116569903","doi":"10.1053/j.seminoncol.2005.04.014","title":"Introduction: Non-Small Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Internal medicine","score_opus":0.008520434493519578,"score_gpt":0.3504902629080791,"score_spread":0.34196982841455953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2116569903","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007556203,0.12679023,0.010516829,0.36659548,0.30583984,0.00034203834,0.00331422,0.0010781555,0.17796694],"genre_scores_gemma":[0.033375163,0.08757634,0.0073627885,0.19952409,0.26809317,0.0004122222,0.0028811127,0.00038820272,0.40038687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994344,0.00012768824,0.00005817019,0.00015176895,0.00016106831,0.00006687588],"domain_scores_gemma":[0.99854016,0.00045077267,0.000096126045,0.000052271247,0.0004156772,0.0004449913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001326326,0.00077547156,0.0009151375,0.0011166049,0.0008033369,0.0013198842,0.0009687832,0.0029991074,0.06121698],"category_scores_gemma":[0.0022016997,0.0002551144,0.00059958326,0.00079114275,0.0006706623,0.0015440757,0.0013275027,0.0032411166,0.027105961],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011958361,0.00007821042,0.00084357563,0.0010897276,0.000015319773,0.00075471634,0.000072961746,0.00010442938,0.0013245494,0.0060821204,0.7884294,0.20108546],"study_design_scores_gemma":[0.000032919987,0.00012382155,0.0020662784,0.00034182388,0.000017020975,0.002672023,0.000039833456,0.000069645175,0.0003826348,0.003042729,0.9911972,0.000014127257],"about_ca_topic_score_codex":0.00044666737,"about_ca_topic_score_gemma":0.0009849205,"teacher_disagreement_score":0.06121698,"about_ca_system_score_codex":0.0008171117,"about_ca_system_score_gemma":0.0012565152,"threshold_uncertainty_score":0.20479119},"labels":[],"label_agreement":null},{"id":"W2117206782","doi":"10.1053/j.seminoncol.2007.07.010","title":"Clinically Relevant Biology of Hereditary Breast Cancer","year":2007,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; BRCA2 Protein; Identification (biology); Gene; Epidemiology; Cancer; Genetics; Mutation; Bioinformatics; Computational biology; Pathology; Biology; Germline mutation; Internal medicine","score_opus":0.04336574340209221,"score_gpt":0.4329801532678643,"score_spread":0.3896144098657721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117206782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007320951,0.99779487,0.0002172538,0.0004779962,0.0004909988,0.00000280626,0.000008188203,0.000007553656,0.00092711963],"genre_scores_gemma":[0.00078749115,0.996932,0.0002636825,0.00044155002,0.00082943786,0.0000064392875,0.00002226234,0.0000015312688,0.00071563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998062,0.000045325032,0.000022321074,0.00003251273,0.00007158264,0.00002208856],"domain_scores_gemma":[0.9996798,0.00018505278,0.000025910793,0.000013539078,0.00006741039,0.000028263215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007131008,0.0012783805,0.0016097509,0.0019795548,0.00030372883,0.0011229604,0.0014704166,0.0018286747,0.00226368],"category_scores_gemma":[0.0008848828,0.00035523233,0.0003622499,0.0019592824,0.0012483348,0.0012777951,0.00076108245,0.00235619,0.0016826477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009602713,0.000072966555,0.00042910254,0.008475424,0.000068320056,0.0012469555,0.00007359834,0.0007337278,0.0026444006,0.011622499,0.11392988,0.860607],"study_design_scores_gemma":[0.00002618429,0.00004098403,0.00090755685,0.0017128735,0.00006807842,0.006227015,0.000059888043,0.00012258346,0.0005275141,0.0057950546,0.9844939,0.000018369738],"about_ca_topic_score_codex":0.0008418157,"about_ca_topic_score_gemma":0.0015420604,"teacher_disagreement_score":0.00226368,"about_ca_system_score_codex":0.0012828998,"about_ca_system_score_gemma":0.0010423999,"threshold_uncertainty_score":0.009308159},"labels":[],"label_agreement":null},{"id":"W2119780823","doi":"10.1053/j.seminoncol.2009.03.003","title":"Cancer in Young Adults 20 to 39 Years of Age: Overview","year":2009,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster Children's Hospital","funders":"","keywords":"Medicine; Psychosocial; Young adult; Cancer; Epidemiology; Disease; Etiology; Ethnic group; Gerontology; Depression (economics); Pediatrics; Psychiatry; Internal medicine","score_opus":0.05565798392498606,"score_gpt":0.4336531959786632,"score_spread":0.37799521205367714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119780823","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001749046,0.9994167,0.000015672988,0.000114669914,0.000048566246,0.0000043267387,0.000025590978,0.0000014109321,0.00019822616],"genre_scores_gemma":[0.0010136429,0.99869305,0.000047051442,0.00009168962,0.000039303653,0.0000061061764,0.000018971054,2.39421e-7,0.000089969704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998318,0.000031312957,0.00004430637,0.000027061633,0.000046752153,0.000018703582],"domain_scores_gemma":[0.99952435,0.00023952631,0.00014115417,0.000004469447,0.00006135368,0.000029131506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043715563,0.00067461375,0.0017136061,0.0027483867,0.00021521539,0.0005869807,0.00041907743,0.00062849256,0.0020849819],"category_scores_gemma":[0.0009486169,0.0002742789,0.0008436397,0.0030977393,0.00019427465,0.0007593753,0.00045945522,0.00063115923,0.00028232302],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000121338766,0.00007548601,0.0022956077,0.10338358,0.0005484876,0.0002659293,0.00015043616,0.00021083977,0.00038698202,0.0007137789,0.024244055,0.8676035],"study_design_scores_gemma":[0.0001486001,0.0006814282,0.040406663,0.15499616,0.0053694407,0.0056337705,0.0009148362,0.0002150982,0.00050331786,0.0010022208,0.7900573,0.00007120195],"about_ca_topic_score_codex":0.0051317737,"about_ca_topic_score_gemma":0.016898135,"teacher_disagreement_score":0.0051317737,"about_ca_system_score_codex":0.0008240419,"about_ca_system_score_gemma":0.0019083122,"threshold_uncertainty_score":0.010203838},"labels":[],"label_agreement":null},{"id":"W2122479458","doi":"10.1053/j.seminoncol.2011.03.016","title":"Pharmacologic Management of Cancer-Related Pain, Dyspnea, and Nausea","year":2011,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Nausea and vomiting management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research; BC Cancer Agency","funders":"","keywords":"Medicine; Nausea; Palliative care; Cancer pain; Cancer; Intensive care medicine; Pain medicine; Randomized controlled trial; Clinical trial; Distress; Surgery; Internal medicine; Anesthesia","score_opus":0.06969079970934558,"score_gpt":0.4307987234994413,"score_spread":0.3611079237900957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122479458","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013551266,0.99902976,0.000084404375,0.00009793619,0.00008649171,0.0000056594445,0.000011776188,0.000006045691,0.00054233556],"genre_scores_gemma":[0.0010517163,0.9980312,0.0002699267,0.00017061316,0.00013295822,0.0000071049235,0.000024862105,0.0000010992242,0.00031051846],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998312,0.000026856758,0.00003381922,0.000028640394,0.00006605915,0.000013431703],"domain_scores_gemma":[0.9997002,0.00016039002,0.00006488425,0.00000659239,0.000049409085,0.000018595267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041579313,0.0007374254,0.0016883524,0.001463763,0.00022070736,0.0005609912,0.00089801167,0.000667869,0.0029662452],"category_scores_gemma":[0.00075002474,0.0002547107,0.0006396311,0.0013567124,0.00031052285,0.00071580324,0.00043240658,0.0015746603,0.0009403313],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009003587,0.00011840624,0.00020523547,0.015393336,0.00016797238,0.00012648664,0.000024752097,0.00017117593,0.00084242725,0.0004886208,0.013116656,0.969255],"study_design_scores_gemma":[0.00032948406,0.000728783,0.007476647,0.018541533,0.0013309688,0.005279337,0.00015961888,0.0004779781,0.001345879,0.0017707257,0.96249986,0.000059319827],"about_ca_topic_score_codex":0.0012654328,"about_ca_topic_score_gemma":0.003252522,"teacher_disagreement_score":0.0029662452,"about_ca_system_score_codex":0.00033089955,"about_ca_system_score_gemma":0.00061502826,"threshold_uncertainty_score":0.0099231005},"labels":[],"label_agreement":null},{"id":"W2122748411","doi":"10.1053/j.seminoncol.2010.06.004","title":"Bisphosphonates in Lung Cancer: More Than a Palliative Therapy?","year":2010,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Novartis Pharmaceuticals Corporation; Bayer Corporation; Bristol-Myers Squibb","keywords":"Medicine; Zoledronic acid; Lung cancer; Cancer; Oncology; Internal medicine; Clinical trial; Adjuvant therapy; Palliative care; Surgery; Nursing","score_opus":0.047669674698986975,"score_gpt":0.4557951072149968,"score_spread":0.4081254325160098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122748411","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033998636,0.9989661,0.000027561257,0.00047518284,0.00022099962,8.724568e-7,0.0000044255994,0.0000020343716,0.0002689143],"genre_scores_gemma":[0.0004581767,0.9981229,0.00007544506,0.0006745812,0.0003840579,0.0000020861967,0.000009321763,8.199644e-7,0.00027263266],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996724,0.00008107846,0.000062843596,0.000049416292,0.00010571106,0.000028556213],"domain_scores_gemma":[0.99927515,0.00037865998,0.00013316215,0.000014766038,0.00014536675,0.00005293128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009245653,0.0008498993,0.0025722466,0.0019766844,0.00030977122,0.0015206502,0.0010405662,0.0018603827,0.004218816],"category_scores_gemma":[0.0014621051,0.00038339756,0.0005642535,0.0030645165,0.00083866407,0.0020681305,0.0007631715,0.0025729279,0.001820098],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013459501,0.00006199102,0.00017630369,0.019204501,0.000153182,0.00021259916,0.00006962994,0.00016303184,0.0006795288,0.0024661664,0.06557799,0.9111005],"study_design_scores_gemma":[0.00011744507,0.00014603458,0.0012188115,0.012762253,0.0004263942,0.0023520263,0.00013769719,0.000115553936,0.00019008448,0.0018731605,0.98062825,0.000032309137],"about_ca_topic_score_codex":0.0019313985,"about_ca_topic_score_gemma":0.005731162,"teacher_disagreement_score":0.004218816,"about_ca_system_score_codex":0.00088688976,"about_ca_system_score_gemma":0.0016038395,"threshold_uncertainty_score":0.014113367},"labels":[],"label_agreement":null},{"id":"W2127462608","doi":"10.1053/j.seminoncol.2004.07.020","title":"Maximizing clinical benefit with trastuzumab","year":2004,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Trastuzumab; Medicine; Vinorelbine; Oncology; Metastatic breast cancer; Internal medicine; Taxane; Capecitabine; Breast cancer; Chemotherapy; Gemcitabine; Clinical trial; Cancer; Colorectal cancer","score_opus":0.17623130803002254,"score_gpt":0.5363274342574647,"score_spread":0.36009612622744214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127462608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021099776,0.9972108,0.00019884208,0.0007265542,0.00020094647,0.0000055671467,0.00001387,0.000008864787,0.0014235914],"genre_scores_gemma":[0.0021304965,0.9954755,0.00021748156,0.0006765762,0.00037193333,0.000011768911,0.000022906961,0.000002230723,0.0010911174],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997851,0.000062004685,0.000032188538,0.000033137072,0.0000623674,0.00002527206],"domain_scores_gemma":[0.99962914,0.00025140398,0.000060078,0.000011055257,0.000033011358,0.000015291755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078056974,0.0010765207,0.002016573,0.0013463713,0.00017542312,0.0008587321,0.0007462128,0.0009830606,0.0045897947],"category_scores_gemma":[0.0012106409,0.00026158657,0.00041287072,0.0014119496,0.0004275874,0.0012241062,0.0005522033,0.0015847349,0.001279965],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002263628,0.00006397857,0.00009368095,0.007417385,0.00013100899,0.00015856231,0.000021006425,0.0004883896,0.00095748866,0.0027697743,0.031857125,0.9558152],"study_design_scores_gemma":[0.00033045563,0.0002979087,0.0011439967,0.005455143,0.00056855544,0.0017011755,0.00003720804,0.00027962722,0.0014452076,0.0044748723,0.9842444,0.000021397513],"about_ca_topic_score_codex":0.0005150911,"about_ca_topic_score_gemma":0.0017029608,"teacher_disagreement_score":0.0045897947,"about_ca_system_score_codex":0.0009720682,"about_ca_system_score_gemma":0.00072632247,"threshold_uncertainty_score":0.015354395},"labels":[],"label_agreement":null},{"id":"W2130773839","doi":"10.1016/s0093-7754(01)90290-8","title":"The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy","year":2001,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":130,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"National Cancer Institute","keywords":"PTEN; Cancer research; Medicine; Ovarian cancer; Breast cancer; Carcinogenesis; Cowden syndrome; Tumor suppressor gene; Oncology; PI3K/AKT/mTOR pathway; Cancer; Internal medicine; Signal transduction; Biology; Genetics","score_opus":0.010687799143218856,"score_gpt":0.2841705723610131,"score_spread":0.27348277321779424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130773839","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020146386,0.9980008,0.00020465089,0.00051826,0.00020479575,0.0000027664664,0.000013020894,0.000007971334,0.00084629166],"genre_scores_gemma":[0.0012646819,0.99739885,0.00025965663,0.00022606549,0.00026664982,0.0000048917764,0.000020251058,0.0000010747826,0.0005579362],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978,0.000044527515,0.000027760076,0.000034122655,0.00009104592,0.000022533168],"domain_scores_gemma":[0.9994808,0.00030030735,0.00004746131,0.000015098739,0.000108031076,0.00004839902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010411727,0.00082043034,0.0016119619,0.001601411,0.0002574177,0.0009250697,0.0012251426,0.0014322058,0.0018659757],"category_scores_gemma":[0.0011269292,0.00023763232,0.00033615628,0.0021214322,0.0006238383,0.0009920218,0.00045087162,0.0016485553,0.0015029587],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021355369,0.00008859455,0.0007106017,0.0030542682,0.00008960169,0.00060982717,0.000034224224,0.0006244129,0.0016894866,0.0027125177,0.033755206,0.9564176],"study_design_scores_gemma":[0.000094358904,0.00021727574,0.004342352,0.0017018943,0.00025331276,0.00566148,0.00009432759,0.00032668596,0.0009820957,0.0043862266,0.981902,0.000037907022],"about_ca_topic_score_codex":0.0015965749,"about_ca_topic_score_gemma":0.0033474935,"teacher_disagreement_score":0.0018659757,"about_ca_system_score_codex":0.00082790793,"about_ca_system_score_gemma":0.0009652081,"threshold_uncertainty_score":0.006242335},"labels":[],"label_agreement":null},{"id":"W2130986264","doi":"10.1016/s0093-7754(01)90297-0","title":"Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials","year":2001,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Docetaxel; Medicine; Vinorelbine; Ifosfamide; Lung cancer; Chemotherapy; Internal medicine; Oncology; Phases of clinical research; Cancer; Surgery; Cisplatin","score_opus":0.1612092728561817,"score_gpt":0.5138659854352491,"score_spread":0.3526567125790674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130986264","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013787018,0.9978073,0.00007434814,0.00019950671,0.0000514201,0.00002690858,0.00007974733,0.0000052316764,0.00037687566],"genre_scores_gemma":[0.0070766783,0.991964,0.00023062353,0.00034798798,0.000040845367,0.000022774318,0.000083161,0.0000020230232,0.00023186932],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99978036,0.00007000896,0.00004586197,0.000037531896,0.00005314514,0.000013106522],"domain_scores_gemma":[0.9990514,0.00070130295,0.00013864395,0.000015375337,0.00006336272,0.000029908691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013153214,0.00069847493,0.0033579252,0.00096815854,0.00017175486,0.00067401835,0.0007553059,0.00068117824,0.0021971497],"category_scores_gemma":[0.0015793631,0.00025621985,0.0015392115,0.0016344284,0.00025498527,0.0005255483,0.00021282342,0.00081907626,0.00031566733],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025123032,0.000119962024,0.00065184076,0.09037754,0.00255554,0.0002354753,0.00007863874,0.0005119068,0.0016274129,0.00040050122,0.01178059,0.8891482],"study_design_scores_gemma":[0.011178607,0.010444779,0.028010337,0.08022431,0.05029492,0.007610886,0.00043170527,0.0007899757,0.0052456376,0.0019832393,0.8036032,0.00018249906],"about_ca_topic_score_codex":0.0013976124,"about_ca_topic_score_gemma":0.0063271257,"teacher_disagreement_score":0.0033579252,"about_ca_system_score_codex":0.00058813713,"about_ca_system_score_gemma":0.0009895132,"threshold_uncertainty_score":0.0073502064},"labels":[],"label_agreement":null},{"id":"W2139267872","doi":"10.1053/j.seminoncol.2009.07.002","title":"Introduction—Impact of Malignant Diseases on Young Adults II","year":2009,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Skin Protection and Aging","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Skin cancer; Psychological intervention; Randomized controlled trial; Intervention (counseling); Young adult; Sun protection; Cancer; Incidence (geometry); Sun exposure; Dermatology; Gerontology; Surgery; Internal medicine; Psychiatry","score_opus":0.008792579588856292,"score_gpt":0.3212122971257511,"score_spread":0.3124197175368948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139267872","genre_codex":"other","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16905323,0.14591998,0.0021242916,0.16428404,0.07403254,0.0005398838,0.056308232,0.00072922796,0.3870086],"genre_scores_gemma":[0.5378237,0.13749963,0.0029641902,0.06977034,0.056255065,0.0004736889,0.024315251,0.0002294228,0.17066874],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978966,0.000037963728,0.00002074796,0.000037593465,0.00006794007,0.000046120873],"domain_scores_gemma":[0.9994043,0.000120317985,0.000087726665,0.000017091366,0.00018133668,0.00018922558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044608949,0.00023759494,0.00020743601,0.00079751806,0.00041575215,0.0010014642,0.0002764901,0.00068514294,0.02261909],"category_scores_gemma":[0.0011735801,0.000107728985,0.00025030607,0.0010133007,0.00016292646,0.0007368936,0.0006251128,0.00077023514,0.0037911243],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026728574,0.00015527161,0.0749399,0.002020277,0.00005066364,0.00061244366,0.0008377734,0.00021883947,0.0015568685,0.0039238282,0.67215025,0.24326663],"study_design_scores_gemma":[0.000026964195,0.00027750467,0.35656923,0.0015005717,0.000048798105,0.0010572572,0.0014321683,0.00007699823,0.0006515933,0.00096896756,0.637367,0.000022902726],"about_ca_topic_score_codex":0.005151142,"about_ca_topic_score_gemma":0.006375944,"teacher_disagreement_score":0.02261909,"about_ca_system_score_codex":0.0004981388,"about_ca_system_score_gemma":0.0007668476,"threshold_uncertainty_score":0.075668395},"labels":[],"label_agreement":null},{"id":"W2139472998","doi":"10.1053/j.seminoncol.2005.09.008","title":"Gene Therapy of the Typical Multidrug Resistance Phenotype of Cancers: A New Hope?","year":2005,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"RNA Interference and Gene Delivery","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University","funders":"","keywords":"Medicine; Clinical trial; Multiple drug resistance; Mechanism (biology); Genetic enhancement; Phenotype; Bioinformatics; Gene; Drug resistance; Computational biology; Biology; Genetics; Internal medicine","score_opus":0.035102224983052516,"score_gpt":0.35328724436733006,"score_spread":0.31818501938427757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139472998","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017354892,0.9945522,0.0010125139,0.0019976387,0.0009815146,0.000005374913,0.000013629955,0.000035316112,0.0012283021],"genre_scores_gemma":[0.001156829,0.9948126,0.00079755794,0.0013306864,0.00059533434,0.0000135192895,0.000028456983,0.0000061271867,0.0012589167],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979705,0.000047828526,0.000019394483,0.00003346742,0.0000731172,0.000029202716],"domain_scores_gemma":[0.99967873,0.00017538933,0.000026529675,0.000021811331,0.0000621641,0.000035306653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010844077,0.0012450088,0.0023573807,0.0011021328,0.00033217206,0.0013279123,0.0017868791,0.0022800711,0.002634048],"category_scores_gemma":[0.00081289664,0.00028793063,0.00058349397,0.0014248054,0.0017397352,0.0027057608,0.00062952813,0.0040292083,0.0027017004],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025583734,0.0001702519,0.00019088012,0.006106172,0.000103223414,0.00047303378,0.00011353189,0.00054651866,0.009761889,0.02295814,0.10237248,0.85694796],"study_design_scores_gemma":[0.000078601326,0.00015217836,0.00033458957,0.00087191554,0.000060704177,0.0014436367,0.00006358989,0.000119081626,0.0016968104,0.00693324,0.9882153,0.000030407036],"about_ca_topic_score_codex":0.00081015646,"about_ca_topic_score_gemma":0.0016881011,"teacher_disagreement_score":0.002634048,"about_ca_system_score_codex":0.0009374892,"about_ca_system_score_gemma":0.0008395539,"threshold_uncertainty_score":0.008811772},"labels":[],"label_agreement":null},{"id":"W2156093622","doi":"10.1053/j.seminoncol.2009.03.005","title":"Psychosocial Issues and Quality of Life","year":2009,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Psychosocial; Medicine; Generativity; Quality of life (healthcare); Psychological intervention; Gerontology; Compromise; Childhood cancer; Cancer; Developmental psychology; Psychiatry; Nursing; Psychology","score_opus":0.11098618069487141,"score_gpt":0.48913571601031897,"score_spread":0.37814953531544754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156093622","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017088966,0.99915874,0.000019511846,0.0001850066,0.000104618586,0.000002932576,0.000011812929,0.000001095624,0.00034538493],"genre_scores_gemma":[0.0018137115,0.99767286,0.00007218275,0.00015869753,0.000103194885,0.0000071697737,0.000017559189,3.611963e-7,0.00015435583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997124,0.00007708648,0.00005184703,0.00003654416,0.00010053732,0.000021526208],"domain_scores_gemma":[0.9992841,0.0004172595,0.00016681364,0.000009123481,0.00008392894,0.000038750524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069137843,0.0007922065,0.0015427081,0.0021743588,0.00027334143,0.0009500509,0.00058056845,0.0007439995,0.0027487539],"category_scores_gemma":[0.0017644236,0.00025310568,0.00071746926,0.003286697,0.0004959199,0.00083371234,0.0007430738,0.0012788123,0.00036943532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000061716826,0.00009536417,0.0018767129,0.040150985,0.0005459377,0.000103453065,0.000109064065,0.00015893277,0.0001871677,0.00091013225,0.018060213,0.93774027],"study_design_scores_gemma":[0.00013152328,0.00033779314,0.04491641,0.11723626,0.003711303,0.0026641053,0.0011059402,0.00023566204,0.00040920125,0.00304319,0.8261204,0.00008828776],"about_ca_topic_score_codex":0.0027924678,"about_ca_topic_score_gemma":0.008399051,"teacher_disagreement_score":0.0027924678,"about_ca_system_score_codex":0.00076202553,"about_ca_system_score_gemma":0.0012757927,"threshold_uncertainty_score":0.009195507},"labels":[],"label_agreement":null},{"id":"W2156946556","doi":"10.1053/sonc.2002.31672","title":"Radioembolization for hepatic metastases","year":2002,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital","funders":"","keywords":"Medicine; Radiology; Nuclear medicine","score_opus":0.08558073659995405,"score_gpt":0.3146175871290862,"score_spread":0.22903685052913217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156946556","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8443268,0.09209552,0.0059934966,0.008121309,0.00080098695,0.00010168239,0.0003000077,0.00026372893,0.04799641],"genre_scores_gemma":[0.97239685,0.018345403,0.0010531681,0.00044504218,0.0008324694,0.00003219512,0.00017958811,0.000035717592,0.006679642],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999387,0.000015654654,0.000004600783,0.0000055733385,0.0000135137125,0.000021871252],"domain_scores_gemma":[0.9998839,0.000050731258,0.000017357022,0.00001495162,0.000007294416,0.000025715284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023547976,0.000164265,0.00037028632,0.0005802366,0.0002602425,0.00022600341,0.00018673927,0.0002740264,0.0039159637],"category_scores_gemma":[0.00081420527,0.00006818369,0.00021796985,0.0005235416,0.0002789954,0.00034282214,0.00020243612,0.00032020392,0.0009131596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0100489585,0.0004466063,0.081501596,0.0007707456,0.00021418292,0.014832121,0.0002962918,0.0013320333,0.027918462,0.0021479842,0.012045809,0.84844524],"study_design_scores_gemma":[0.0019186578,0.010761006,0.659446,0.00031894483,0.0007779829,0.15642391,0.00040241616,0.00260057,0.049726564,0.008206138,0.109329,0.000088862966],"about_ca_topic_score_codex":0.00067115185,"about_ca_topic_score_gemma":0.00095863064,"teacher_disagreement_score":0.0039159637,"about_ca_system_score_codex":0.00040430957,"about_ca_system_score_gemma":0.00032743753,"threshold_uncertainty_score":0.013100207},"labels":[],"label_agreement":null},{"id":"W2162641301","doi":"10.1053/j.seminoncol.2015.07.003","title":"The Globalization of Cooperative Groups","year":2015,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Impact; Queen's University","funders":"Canadian Cancer Society Research Institute; National Institutes of Health; National Cancer Institute; Bill and Melinda Gates Foundation","keywords":"Medicine; Latin Americans; Clinical trial; Cancer; Globalization; Family medicine; Working group; Economic growth; Political science; Pathology; Internal medicine; Law","score_opus":0.0252713700555133,"score_gpt":0.36049856834563615,"score_spread":0.3352271982901229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162641301","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000368949,0.95246726,0.0012056174,0.021777233,0.0032241049,0.000014119998,0.00002293765,0.000020633304,0.020899165],"genre_scores_gemma":[0.01158352,0.9595868,0.0011477171,0.01261588,0.004300423,0.00006996931,0.00007422277,0.000016565116,0.010604774],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99813914,0.0007967976,0.00006962394,0.00022893169,0.0005057982,0.00025967523],"domain_scores_gemma":[0.9968616,0.0017542753,0.00035444854,0.00015560904,0.00037798347,0.0004959977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036374035,0.0008128362,0.00079898495,0.001882202,0.00113057,0.0043906104,0.0019558996,0.0043224753,0.010793729],"category_scores_gemma":[0.0049774353,0.00032457538,0.00048764626,0.0032225149,0.005126559,0.00759024,0.005083511,0.0042069615,0.002771854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004475601,0.000060089485,0.00032530382,0.0032413916,0.000030573763,0.0003208584,0.001028208,0.00028969636,0.00024653244,0.26332146,0.17913799,0.5519531],"study_design_scores_gemma":[0.000006022812,0.000008636236,0.00016771369,0.0014054285,0.000004826555,0.000184663,0.00025246822,0.000025133873,0.000027289381,0.014925317,0.9829873,0.0000052042433],"about_ca_topic_score_codex":0.0019433635,"about_ca_topic_score_gemma":0.0029732042,"teacher_disagreement_score":0.010793729,"about_ca_system_score_codex":0.0034948492,"about_ca_system_score_gemma":0.004229926,"threshold_uncertainty_score":0.036108553},"labels":[],"label_agreement":null},{"id":"W2170700422","doi":"10.1053/j.seminoncol.2009.12.005","title":"Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators","year":2010,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; FOLFOX; Colorectal cancer; Oxaliplatin; Adjuvant; Numeracy; Oncology; Internal medicine; Stage (stratigraphy); Fluorouracil; Adjuvant therapy; Adjuvant chemotherapy; Surgery; Chemotherapy; Cancer; Breast cancer","score_opus":0.03339839090572973,"score_gpt":0.4159180694435799,"score_spread":0.3825196785378502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170700422","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830072,0.015307099,0.0004493927,0.00023681241,0.00008572827,0.000054497817,0.000110920955,0.000019736182,0.0007284899],"genre_scores_gemma":[0.9941401,0.004278834,0.0008583194,0.00010694664,0.00008231513,0.00005005824,0.00017016967,0.000009640521,0.0003035886],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901617,0.0005792772,0.00007581638,0.00009082717,0.0001675801,0.00007032053],"domain_scores_gemma":[0.996716,0.0021489689,0.0005553273,0.00013984866,0.00013111456,0.00030873975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018406888,0.000531021,0.0019338111,0.0007316135,0.000230856,0.000708782,0.00047813842,0.00069270504,0.0007887013],"category_scores_gemma":[0.004958197,0.00022878658,0.00067286403,0.00096402626,0.0004818938,0.0007091691,0.0004620716,0.0011250773,0.0000937924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6099125,0.0050482713,0.10224064,0.0009859162,0.0015907012,0.00017427144,0.0005290182,0.0042333687,0.009346057,0.00059989764,0.0005155988,0.2648237],"study_design_scores_gemma":[0.073741615,0.43731415,0.43180725,0.0004418995,0.009566118,0.0010423152,0.0012228506,0.016885119,0.015521665,0.0011910129,0.011062025,0.00020400017],"about_ca_topic_score_codex":0.00081644126,"about_ca_topic_score_gemma":0.0011003121,"teacher_disagreement_score":0.0019338111,"about_ca_system_score_codex":0.00058863824,"about_ca_system_score_gemma":0.0007110254,"threshold_uncertainty_score":0.009734631},"labels":[],"label_agreement":null},{"id":"W2755955412","doi":"10.1053/j.seminoncol.2017.08.004","title":"Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients","year":2017,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Ovarian cancer; Olaparib; Medicine; Germline; Genetic testing; Germline mutation; PARP inhibitor; Oncology; Cancer; Somatic cell; Breast cancer; Internal medicine; BRCA mutation; Mutation; Cancer research; Gynecology; Polymerase; Poly ADP ribose polymerase; Genetics; DNA; Biology; Gene","score_opus":0.07812918806627712,"score_gpt":0.42382383054090716,"score_spread":0.34569464247463005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755955412","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004730347,0.87269837,0.0026060678,0.0749254,0.0114414925,0.00022639392,0.0012015639,0.00022053832,0.03620709],"genre_scores_gemma":[0.0028782242,0.9232842,0.0059041055,0.044890717,0.0028693255,0.00036703417,0.0019274252,0.000049445047,0.017829569],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880075,0.0003224881,0.00019764788,0.00009708814,0.0004995191,0.00008253542],"domain_scores_gemma":[0.99737906,0.0010577724,0.00031552714,0.00005853075,0.0009923228,0.00019682953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026598854,0.0007200691,0.001006158,0.0015981314,0.00043126897,0.00094861817,0.0020766489,0.0054148217,0.0049840645],"category_scores_gemma":[0.0051250076,0.00039661032,0.0010280018,0.0013131684,0.0008406482,0.0012500808,0.0010391007,0.0049424767,0.0046083843],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039949315,0.000048678558,0.00016282921,0.004263081,0.000027501257,0.00033487898,0.00007096027,0.00024904875,0.0005068471,0.006579933,0.59460884,0.39310744],"study_design_scores_gemma":[0.00001548601,0.00002119945,0.00026046034,0.0029739377,0.000017865625,0.0006140703,0.00001891494,0.000030003841,0.00010998461,0.0012602188,0.9946694,0.000008346502],"about_ca_topic_score_codex":0.0048342086,"about_ca_topic_score_gemma":0.0073654526,"teacher_disagreement_score":0.0054148217,"about_ca_system_score_codex":0.0015287669,"about_ca_system_score_gemma":0.004594688,"threshold_uncertainty_score":0.016673326},"labels":[],"label_agreement":null},{"id":"W2765724600","doi":"10.1053/j.seminoncol.2017.10.009","title":"Management of stage III non–small cell lung cancer","year":2017,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Context (archaeology); Malignancy; Immunotherapy; Lung cancer; Disease; Intensive care medicine; Stage (stratigraphy); Cancer; Radiation therapy; Oncology; Surgery; Internal medicine","score_opus":0.05417943617264763,"score_gpt":0.43365465582967,"score_spread":0.37947521965702236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765724600","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006407899,0.9994191,0.00004209852,0.00011357552,0.000092641516,0.0000022052177,0.0000061879546,0.0000019344184,0.00025809873],"genre_scores_gemma":[0.0010471076,0.9981654,0.00012233322,0.00026854197,0.00019462999,0.0000037735078,0.000023770717,7.693387e-7,0.00017362731],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997588,0.00005319896,0.000043996617,0.00004285432,0.00007879012,0.000022464308],"domain_scores_gemma":[0.99972147,0.00015411945,0.0000560588,0.000005435605,0.00004492949,0.000018009689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050325424,0.0006236453,0.0014189287,0.0013896808,0.00022362608,0.0009501418,0.0010521444,0.0007780789,0.0019957132],"category_scores_gemma":[0.0010593983,0.00021509948,0.00076275604,0.00094369694,0.00040435581,0.00088393525,0.00061799557,0.0013309885,0.0006865917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005844692,0.00003936129,0.00035975277,0.02412737,0.0001645451,0.00022023461,0.000034011577,0.0002929878,0.00047964786,0.0007957826,0.019047115,0.95438075],"study_design_scores_gemma":[0.00009417034,0.00022806933,0.0046751644,0.029717114,0.00091659144,0.005001664,0.00017848691,0.00026832955,0.0004493837,0.0024377955,0.95598066,0.000052537598],"about_ca_topic_score_codex":0.0014523931,"about_ca_topic_score_gemma":0.004228822,"teacher_disagreement_score":0.0019957132,"about_ca_system_score_codex":0.00056500523,"about_ca_system_score_gemma":0.00091623864,"threshold_uncertainty_score":0.0066763163},"labels":[],"label_agreement":null},{"id":"W2792041391","doi":"10.1053/j.seminoncol.2018.01.009","title":"Cell-free DNA as a post-treatment surveillance strategy: current status","year":2017,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation","keywords":"Medicine; Minimal residual disease; Epigenetics; Cell-free fetal DNA; Computational biology; Circulating tumor DNA; Cancer; DNA; Bioinformatics; Internal medicine; Genetics; Biology; Gene","score_opus":0.04472230872259286,"score_gpt":0.39301490682007023,"score_spread":0.34829259809747737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792041391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016669946,0.99824584,0.00032063044,0.00038448581,0.00023544897,0.0000044529734,0.000016646885,0.000009106894,0.0006168716],"genre_scores_gemma":[0.002236645,0.9957924,0.00047696414,0.0005502563,0.00029611491,0.000013500946,0.00005210226,0.0000037401674,0.00057825027],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997037,0.000067317436,0.00002914849,0.00007240036,0.000088139175,0.000039201706],"domain_scores_gemma":[0.9991579,0.0005642122,0.00008834058,0.000024344963,0.00010815903,0.000057033267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011677386,0.0007392798,0.0014447027,0.0010221672,0.00021892399,0.0015616897,0.0011079436,0.0013960951,0.0036613976],"category_scores_gemma":[0.0013376349,0.00022724111,0.00051326206,0.00087924465,0.00093328353,0.0016403993,0.00086278986,0.0019946897,0.001898854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001616073,0.000081101694,0.00027898725,0.008934043,0.00006986317,0.00013507574,0.00004566728,0.00036946766,0.0021118773,0.0042359834,0.016264856,0.96731144],"study_design_scores_gemma":[0.000040634593,0.0003074727,0.0007631979,0.003860518,0.00022663746,0.0014146604,0.000116029514,0.00023165274,0.002400768,0.0034441433,0.9871596,0.000034700668],"about_ca_topic_score_codex":0.000577328,"about_ca_topic_score_gemma":0.0012194843,"teacher_disagreement_score":0.0036613976,"about_ca_system_score_codex":0.0006797658,"about_ca_system_score_gemma":0.0011898092,"threshold_uncertainty_score":0.012248576},"labels":[],"label_agreement":null},{"id":"W2908061515","doi":"10.1053/j.seminoncol.2018.12.006","title":"Medical oncology job satisfaction: Results of a global survey","year":2019,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Healthcare professionals’ stress and burnout","field":"Health Professions","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Medicine; Job satisfaction; Oncology; MEDLINE; Patient satisfaction; Internal medicine; Family medicine; Nursing","score_opus":0.061486399146969926,"score_gpt":0.4884743871861017,"score_spread":0.4269879880391318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908061515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99698526,0.00012834375,0.00009559344,0.00023625803,0.000017762564,0.00003583028,0.00070941076,0.000005523932,0.001786119],"genre_scores_gemma":[0.99808455,0.00012328869,0.00011485141,0.00025479056,0.000020272613,0.00004409783,0.0008186106,0.0000064032156,0.0005332847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982169,0.00069722557,0.00022563462,0.00013018493,0.00031453135,0.0004154947],"domain_scores_gemma":[0.99423486,0.0011773901,0.0015832776,0.00021527737,0.0013522241,0.0014368889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033428892,0.00033850744,0.00042542935,0.0013430639,0.0006153426,0.0007129972,0.00027537544,0.0007313531,0.0015952103],"category_scores_gemma":[0.0052478747,0.00022901643,0.0007350021,0.0017836816,0.0004953477,0.00076809165,0.0014093475,0.000748755,0.0005113951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011386849,0.00020242187,0.99409616,0.000028189777,0.000038459453,0.000034283064,0.0012118955,0.000057982557,0.00016316354,0.0000141192195,0.00052702863,0.0035125467],"study_design_scores_gemma":[0.00000581363,0.0001678996,0.9975522,0.0000057320194,0.000009248589,0.00003759514,0.001706857,0.000050864666,0.000042219395,0.0000059704726,0.00041188736,0.0000036948852],"about_ca_topic_score_codex":0.0032240513,"about_ca_topic_score_gemma":0.0038575123,"teacher_disagreement_score":0.0033428892,"about_ca_system_score_codex":0.0004368332,"about_ca_system_score_gemma":0.0005661991,"threshold_uncertainty_score":0.017679036},"labels":[],"label_agreement":null},{"id":"W3010479561","doi":"10.1053/j.seminoncol.2020.02.007","title":"Current and coming challenges in the management of the survivorship population","year":2020,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health","keywords":"Survivorship curve; Medicine; Psychosocial; Childhood cancer; Epidemiology; Population; Cancer; Gerontology; Cancer survivorship; Pediatrics; Demography; Environmental health; Psychiatry; Pathology; Internal medicine","score_opus":0.1595619280799779,"score_gpt":0.4339071313693772,"score_spread":0.27434520328939926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010479561","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044775847,0.9973181,0.00003699481,0.002155896,0.00024302417,0.0000011329201,0.000006478284,0.000002412054,0.00019111586],"genre_scores_gemma":[0.0005321348,0.99808264,0.00010992967,0.000756812,0.00040961633,0.000003583947,0.000012921635,7.7761575e-7,0.000091645634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991197,0.00031059489,0.00012528145,0.00010079184,0.00025821294,0.000085454325],"domain_scores_gemma":[0.994136,0.0041048406,0.00046842906,0.000051141134,0.0008235111,0.00041596862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041479,0.0006961796,0.002052207,0.0019397645,0.00055341545,0.0024647568,0.0012634137,0.002360879,0.004386641],"category_scores_gemma":[0.005910066,0.00029704886,0.00094398606,0.0031729315,0.0012364762,0.0032113623,0.0015199352,0.0041345297,0.001021454],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067312656,0.000054812343,0.00048242637,0.023679616,0.00013087796,0.000119671844,0.0001667279,0.00034781205,0.00017033132,0.0060879695,0.04309288,0.9255996],"study_design_scores_gemma":[0.00004963647,0.00016941167,0.0034792526,0.061750725,0.00044036433,0.0011137633,0.0012003302,0.00027432118,0.00010076027,0.009292214,0.9220651,0.00006404083],"about_ca_topic_score_codex":0.0047881976,"about_ca_topic_score_gemma":0.012807243,"teacher_disagreement_score":0.0047881976,"about_ca_system_score_codex":0.0022026845,"about_ca_system_score_gemma":0.00563383,"threshold_uncertainty_score":0.021936476},"labels":[],"label_agreement":null},{"id":"W3022810005","doi":"10.1016/s0093-7754(01)90138-1","title":"Surveillance for hepatocellular carcinoma","year":2001,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Cirrhosis; Hepatitis B; Randomized controlled trial; Internal medicine; Intensive care medicine","score_opus":0.1290042608533236,"score_gpt":0.3658405095273251,"score_spread":0.23683624867400152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3022810005","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014422735,0.9968839,0.00012869814,0.00029084145,0.00023386755,0.0000110307465,0.000028437911,0.000008597162,0.002270323],"genre_scores_gemma":[0.0016764351,0.9961831,0.00024812153,0.00048179104,0.0002390277,0.00001873015,0.00008034634,0.000001722105,0.0010705666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995453,0.00014856904,0.00006425942,0.000072241986,0.00013906322,0.000030609845],"domain_scores_gemma":[0.9993606,0.00028682157,0.00014214982,0.00003538426,0.00012390195,0.000051099705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008837685,0.00082054373,0.0014512133,0.002815262,0.00023664565,0.0005887328,0.00068468467,0.0012600907,0.0054654116],"category_scores_gemma":[0.0018098336,0.0001737844,0.00061400566,0.0024896257,0.00039593078,0.0009702033,0.0005371857,0.00085112103,0.0029002593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005594514,0.000033840213,0.0005375271,0.012875306,0.0001227947,0.00015317489,0.00005092445,0.00009266008,0.00041630445,0.0011598986,0.035141353,0.94936025],"study_design_scores_gemma":[0.00006472361,0.00018175085,0.0054759257,0.012106598,0.00031592615,0.004964917,0.00009128397,0.00007119339,0.00040708896,0.0016336375,0.9746653,0.0000216179],"about_ca_topic_score_codex":0.0018069707,"about_ca_topic_score_gemma":0.0028856476,"teacher_disagreement_score":0.0054654116,"about_ca_system_score_codex":0.0005234964,"about_ca_system_score_gemma":0.0010230708,"threshold_uncertainty_score":0.018283665},"labels":[],"label_agreement":null},{"id":"W3094171178","doi":"10.1053/j.seminoncol.2020.10.001","title":"Toward affordable cancer drugs: Do we need firmer price negotiation, me-too drugs, or a biosimilar silver bullet?","year":2020,"lang":"en","type":"editorial","venue":"Seminars in Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Biosimilar; Medicine; Cancer drugs; Negotiation; Cancer; Silver bullet; Drug prices; Pharmacology; Drug; Intensive care medicine; Internal medicine; Public economics","score_opus":0.019932946611267474,"score_gpt":0.3240218381404496,"score_spread":0.3040888915291821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094171178","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020704014,0.0054933713,0.00011137584,0.057618897,0.9354563,0.000010620905,0.000024556348,0.00002897156,0.0012352343],"genre_scores_gemma":[0.00034690372,0.006010284,0.00018996996,0.056633588,0.92822504,0.000018098202,0.000025325195,0.00003962719,0.008511184],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99039054,0.0017937253,0.0010563005,0.00078411354,0.00539629,0.00057894073],"domain_scores_gemma":[0.9584159,0.01965605,0.0017015524,0.00072877563,0.013084339,0.0064133545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01717464,0.0034197692,0.003568618,0.0030020701,0.0030469208,0.011256437,0.0046518147,0.025873818,0.01243518],"category_scores_gemma":[0.0427975,0.0012448676,0.0026702539,0.0014701672,0.003379637,0.00839077,0.0018944183,0.035317376,0.009801858],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023569832,0.000013577458,0.000012990554,0.00016352392,0.000013972363,0.000044357563,0.000009803223,0.00001603298,0.00003317118,0.0005805269,0.994842,0.0042463867],"study_design_scores_gemma":[0.00009410552,0.000043047068,0.00018358999,0.00053789775,0.000052825326,0.00014687968,0.00006370407,0.00017184326,0.000079809215,0.0030797143,0.9955188,0.000027700766],"about_ca_topic_score_codex":0.0025281059,"about_ca_topic_score_gemma":0.007786852,"teacher_disagreement_score":0.025873818,"about_ca_system_score_codex":0.0042587644,"about_ca_system_score_gemma":0.006538382,"threshold_uncertainty_score":0.09082931},"labels":[],"label_agreement":null},{"id":"W3148820128","doi":"10.1053/j.seminoncol.2021.03.001","title":"Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China","year":2021,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Natural Science Foundation of China","keywords":"Medicine; Gefitinib; Erlotinib; Reimbursement; Public economics; Cancer; Economic growth; Epidermal growth factor receptor; Economics; Health care; Internal medicine","score_opus":0.054499248969912276,"score_gpt":0.3286563674087065,"score_spread":0.27415711843879426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148820128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.712553,0.0043742647,0.003563966,0.060250547,0.00023622236,0.00030865122,0.00045450008,0.0001101615,0.2181487],"genre_scores_gemma":[0.9839392,0.00081166765,0.00063717546,0.0023926713,0.000048297803,0.000041405016,0.00008418002,0.000010696697,0.012034612],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99869365,0.0005131152,0.000033321812,0.00007587609,0.00021683674,0.00046726313],"domain_scores_gemma":[0.9982514,0.000717815,0.00019768447,0.00009643564,0.0003039071,0.00043277693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024902378,0.0002618311,0.00044573416,0.0007920597,0.0030115359,0.0025490073,0.0009169032,0.0019505649,0.008461006],"category_scores_gemma":[0.0041299947,0.00013396946,0.0006039525,0.0014428166,0.0020870625,0.0013611848,0.0019098888,0.0020052742,0.00029758032],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026474122,0.0013933664,0.09203155,0.0011610324,0.0005130515,0.010497305,0.012282495,0.026367227,0.0063999323,0.59863204,0.058030505,0.1900441],"study_design_scores_gemma":[0.0032761644,0.0021103173,0.22329818,0.0007312701,0.00079893,0.0010114575,0.020307958,0.051304694,0.008005007,0.15007369,0.5387153,0.00036703266],"about_ca_topic_score_codex":0.15658134,"about_ca_topic_score_gemma":0.16645338,"teacher_disagreement_score":0.15658134,"about_ca_system_score_codex":0.008104506,"about_ca_system_score_gemma":0.011768073,"threshold_uncertainty_score":0.31133986},"labels":[],"label_agreement":null},{"id":"W4225147572","doi":"10.1053/j.seminoncol.2022.04.002","title":"Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab","year":2022,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Renal cell carcinoma; Nephrectomy; Kidney cancer; Adjuvant; Oncology; Internal medicine; Cancer; Adjuvant therapy; Melanoma; Surgery; Immunotherapy; Kidney; Cancer research","score_opus":0.02166250864591987,"score_gpt":0.2929535457220311,"score_spread":0.27129103707611124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225147572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776375,0.0006066833,0.00004132313,0.00023947889,0.000024523712,0.000003414836,0.0003922303,0.0000030031651,0.00092566886],"genre_scores_gemma":[0.99906844,0.0002118328,0.000017353952,0.00005090308,0.000033746684,0.0000032906912,0.00042257327,0.0000010496228,0.00019096387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985635,0.000022290964,0.000010487894,0.00002999022,0.000022219203,0.000058651625],"domain_scores_gemma":[0.99968076,0.000058735914,0.0001158699,0.000012851481,0.000019755855,0.000112053334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014396744,0.00013580317,0.00030675883,0.00027318276,0.000229281,0.0004026347,0.00021385634,0.00036727777,0.001654198],"category_scores_gemma":[0.0008980108,0.00014063263,0.0006180197,0.00041179723,0.0001271657,0.00037241998,0.00032678546,0.0006131688,0.00014455177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008312684,0.000048425318,0.99490523,0.00001701129,0.00012136148,0.00020867324,0.000026433654,0.00018599117,0.0002729959,0.000044717726,0.00040704096,0.0029308903],"study_design_scores_gemma":[0.000017143047,0.00008661578,0.99894506,0.0000052264895,0.00006053437,0.00025278545,0.000075067655,0.00027534526,0.000035269506,0.00005319694,0.0001909248,0.00000302512],"about_ca_topic_score_codex":0.0036232793,"about_ca_topic_score_gemma":0.007024037,"teacher_disagreement_score":0.0036232793,"about_ca_system_score_codex":0.00039539175,"about_ca_system_score_gemma":0.00036756136,"threshold_uncertainty_score":0.007204354},"labels":[],"label_agreement":null},{"id":"W4234456939","doi":"10.1053/sonc.2002.33538","title":"Epoetin alfa in patients not on chemotherapy [ndash ] Canadian data","year":2002,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Epoetin alfa; Medicine; Anemia; Erythropoietin; Chemotherapy; Internal medicine; Cancer; Quality of life (healthcare); Oncology; Darbepoetin alfa; Hemoglobin; Surgery","score_opus":0.04502290979312209,"score_gpt":0.32040501128027976,"score_spread":0.2753821014871577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234456939","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14542884,0.021274999,0.0008901699,0.0070612817,0.0006255302,0.0007282961,0.6945407,0.00014946339,0.12930079],"genre_scores_gemma":[0.741411,0.016318154,0.0022977674,0.005441448,0.00035422144,0.000578455,0.21107014,0.00014966702,0.022379128],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.997954,0.00030268088,0.00032857864,0.00020874495,0.0007293423,0.0004766191],"domain_scores_gemma":[0.9925196,0.00092858996,0.0012537962,0.00042005663,0.0039766785,0.0009012377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014749041,0.00034761347,0.000800397,0.001668559,0.0011071871,0.0010008782,0.0010878966,0.0004260781,0.008563875],"category_scores_gemma":[0.009081762,0.00026208186,0.0012056815,0.007401062,0.0003492108,0.00043371314,0.0004424892,0.0009933998,0.00072237017],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012402533,0.00019856413,0.42333,0.0045022788,0.0017096285,0.00044802864,0.00046057822,0.001707459,0.00072542124,0.0035705739,0.43971452,0.111230396],"study_design_scores_gemma":[0.0022064785,0.0003257902,0.7977357,0.00092014443,0.00132552,0.0003189415,0.0003749225,0.00024859142,0.00073893217,0.00044720861,0.19527407,0.000083674386],"about_ca_topic_score_codex":0.9586359,"about_ca_topic_score_gemma":0.9823821,"teacher_disagreement_score":0.041364074,"about_ca_system_score_codex":0.012428384,"about_ca_system_score_gemma":0.034116074,"threshold_uncertainty_score":0.090174675},"labels":[],"label_agreement":null},{"id":"W4253118244","doi":"10.1016/s0093-7754(01)90200-3","title":"Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trials","year":2001,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Docetaxel; Vinorelbine; Medicine; Ifosfamide; Lung cancer; Chemotherapy; Oncology; Internal medicine; Cancer; Phases of clinical research; Surgery; Cisplatin","score_opus":0.1612092728561817,"score_gpt":0.5138659854352491,"score_spread":0.3526567125790674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253118244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013787018,0.9978073,0.00007434814,0.00019950671,0.0000514201,0.00002690858,0.00007974733,0.0000052316764,0.00037687566],"genre_scores_gemma":[0.0070766783,0.991964,0.00023062353,0.00034798798,0.000040845367,0.000022774318,0.000083161,0.0000020230232,0.00023186932],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99978036,0.00007000896,0.00004586197,0.000037531896,0.00005314514,0.000013106522],"domain_scores_gemma":[0.9990514,0.00070130295,0.00013864395,0.000015375337,0.00006336272,0.000029908691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013153214,0.00069847493,0.0033579252,0.00096815854,0.00017175486,0.00067401835,0.0007553059,0.00068117824,0.0021971497],"category_scores_gemma":[0.0015793631,0.00025621985,0.0015392115,0.0016344284,0.00025498527,0.0005255483,0.00021282342,0.00081907626,0.00031566733],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025123032,0.000119962024,0.00065184076,0.09037754,0.00255554,0.0002354753,0.00007863874,0.0005119068,0.0016274129,0.00040050122,0.01178059,0.8891482],"study_design_scores_gemma":[0.011178607,0.010444779,0.028010337,0.08022431,0.05029492,0.007610886,0.00043170527,0.0007899757,0.0052456376,0.0019832393,0.8036032,0.00018249906],"about_ca_topic_score_codex":0.0013976124,"about_ca_topic_score_gemma":0.0063271257,"teacher_disagreement_score":0.0033579252,"about_ca_system_score_codex":0.00058813713,"about_ca_system_score_gemma":0.0009895132,"threshold_uncertainty_score":0.0073502064},"labels":[],"label_agreement":null},{"id":"W4255539843","doi":"10.1053/sonc.2002.34067","title":"Evidence for erythropoietin as a molecular targeting agent","year":2002,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Erythropoietin; Medicine; Hypoxia (environmental); Cancer research; Signal transduction; Hypoxia-inducible factors; STAT5; Cytokine; Tyrosine kinase; Erythropoiesis; Immunology; Anemia; Bioinformatics; Cell biology; Internal medicine; Biology; Receptor; Gene; Chemistry","score_opus":0.1700107563064165,"score_gpt":0.4648524944731977,"score_spread":0.2948417381667812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4255539843","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023131885,0.9973335,0.00021652097,0.00044515284,0.00022183348,0.000004862031,0.00001473514,0.000006996758,0.0015250165],"genre_scores_gemma":[0.0018274029,0.99568224,0.0005328117,0.0007479846,0.00031668853,0.000013761177,0.00003700069,0.0000035341118,0.00083847117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977976,0.00004610467,0.00003319981,0.00004420859,0.00007858631,0.000018140106],"domain_scores_gemma":[0.9992448,0.000534241,0.00006676004,0.00002370523,0.0000990206,0.000031538246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011825897,0.0008064029,0.0015584129,0.0017173518,0.00031974635,0.0011739944,0.0010075335,0.0016505065,0.0037053123],"category_scores_gemma":[0.0013197146,0.00028171076,0.0005584416,0.0017390498,0.00077592954,0.001236038,0.0006619705,0.0022899082,0.0020017836],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039718385,0.00013090354,0.00023990321,0.010531905,0.000132642,0.0010419191,0.000047717796,0.00038059332,0.006724362,0.0052552116,0.025493838,0.94962376],"study_design_scores_gemma":[0.00012484186,0.0002394214,0.0006829369,0.0024503917,0.0002640038,0.0031049543,0.000040452327,0.00008839587,0.0032434906,0.0021253598,0.98761636,0.000019375064],"about_ca_topic_score_codex":0.0008297181,"about_ca_topic_score_gemma":0.0011199601,"teacher_disagreement_score":0.0037053123,"about_ca_system_score_codex":0.00067653693,"about_ca_system_score_gemma":0.0009572151,"threshold_uncertainty_score":0.012395561},"labels":[],"label_agreement":null},{"id":"W4295102979","doi":"10.1053/j.seminoncol.2022.09.002","title":"Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)","year":2022,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pandemic; Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Center (category theory); Hematology; Cancer; Internal medicine; Clinical Oncology; Oncology; Family medicine; Virology; Infectious disease (medical specialty); Disease","score_opus":0.07196332846593904,"score_gpt":0.45046123820903233,"score_spread":0.3784979097430933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295102979","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06948267,0.0044868486,0.00011386188,0.87666386,0.0048868614,0.000028636821,0.00042597204,0.000022937418,0.04388838],"genre_scores_gemma":[0.6901959,0.020836852,0.00085048814,0.25257128,0.008114021,0.00012981938,0.0007676906,0.00008901948,0.02644498],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9967674,0.0011632377,0.00007883708,0.000120287434,0.0004746946,0.0013956467],"domain_scores_gemma":[0.9848764,0.0012642691,0.0009938848,0.00016891018,0.0012654645,0.0114311995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00396455,0.00023412712,0.0002978846,0.00055440434,0.0050099324,0.0049095154,0.0006149849,0.0027082427,0.022563385],"category_scores_gemma":[0.011957267,0.00017928763,0.00039705867,0.00062325347,0.0022757363,0.0021132987,0.008502857,0.0052984986,0.0013886264],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021787766,0.00042723396,0.06678587,0.0003554624,0.0000721002,0.0016629853,0.015100133,0.0004172408,0.0006684564,0.02454119,0.7774821,0.1122694],"study_design_scores_gemma":[0.00006248282,0.00048802025,0.111809134,0.0015435149,0.000049546958,0.0011269193,0.07996954,0.00033637625,0.00043475907,0.011545376,0.79252356,0.000110713896],"about_ca_topic_score_codex":0.017964955,"about_ca_topic_score_gemma":0.044071686,"teacher_disagreement_score":0.022563385,"about_ca_system_score_codex":0.005438594,"about_ca_system_score_gemma":0.016859435,"threshold_uncertainty_score":0.07548207},"labels":[],"label_agreement":null},{"id":"W4307160114","doi":"10.1053/j.seminoncol.2022.10.001","title":"IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time","year":2022,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Ipilimumab; Cabozantinib; Pembrolizumab; Axitinib; Sunitinib; Renal cell carcinoma; Oncology; Kidney cancer; Hazard ratio; Clinical trial; Progression-free survival; Cancer; Immunotherapy; Overall survival; Confidence interval","score_opus":0.03645426860760719,"score_gpt":0.3739355171632866,"score_spread":0.3374812485556794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307160114","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024979275,0.995684,0.00014945175,0.00020611697,0.00014071648,0.00032627702,0.0008081477,0.000013339785,0.00017399032],"genre_scores_gemma":[0.08208234,0.9135358,0.0010575255,0.0014596051,0.00012790588,0.00083562743,0.00059434836,0.000020522593,0.00028636787],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9938212,0.0021127388,0.0023917658,0.0006645683,0.00069067336,0.0003191356],"domain_scores_gemma":[0.9851981,0.008508842,0.0048846267,0.00025233117,0.0009105367,0.00024554465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007954274,0.0014921892,0.011746671,0.0048859944,0.00039497076,0.0027076053,0.0011781551,0.0017183078,0.004427825],"category_scores_gemma":[0.027708367,0.0011544301,0.016609471,0.0061223223,0.00092537963,0.0021974004,0.0019897693,0.0019420424,0.0003103104],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018276705,0.000022672428,0.0020325265,0.88419676,0.09319116,0.00005665343,0.00020103724,0.00015909164,0.0002783404,0.00012671607,0.0010392606,0.016868081],"study_design_scores_gemma":[0.0032512292,0.00065558514,0.008688398,0.35351148,0.6224212,0.00021147294,0.00028487996,0.0001352694,0.00022132132,0.0002930576,0.010257205,0.000068807414],"about_ca_topic_score_codex":0.010385138,"about_ca_topic_score_gemma":0.039131634,"teacher_disagreement_score":0.011746671,"about_ca_system_score_codex":0.004387816,"about_ca_system_score_gemma":0.007292853,"threshold_uncertainty_score":0.042066693},"labels":[],"label_agreement":null},{"id":"W4408324658","doi":"10.1053/j.seminoncol.2025.01.002","title":"Plant polyphenols in gastric cancer: Nature's healing touch","year":2025,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"Phytochemicals and Antioxidant Activities","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre","funders":"","keywords":"Medicine; Cancer; Polyphenol; Wound healing; Surgery; Internal medicine; Biochemistry","score_opus":0.028626191522679804,"score_gpt":0.39805690612168926,"score_spread":0.36943071459900945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408324658","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043172517,0.9988809,0.000024210405,0.00048122936,0.00030649817,7.4819695e-7,0.000004321071,0.0000021999897,0.00025675053],"genre_scores_gemma":[0.0005790681,0.99768925,0.00007007232,0.00059836346,0.0005812777,0.0000016803529,0.000009056473,7.787495e-7,0.00047040722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998486,0.00003316248,0.000019500701,0.000025862653,0.00005394745,0.000018764786],"domain_scores_gemma":[0.99958485,0.00021398054,0.000046749614,0.000012236326,0.00009625627,0.000045930992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070015976,0.0006613233,0.0014171678,0.0016452498,0.00027663962,0.0013809083,0.0006601423,0.0014784025,0.0038487727],"category_scores_gemma":[0.0007003776,0.00019777645,0.00051290577,0.0022257313,0.0005899258,0.0018249124,0.0007344445,0.0025025345,0.0014140179],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018716707,0.00010392955,0.00024353404,0.016695078,0.00013723019,0.0002309951,0.00010138193,0.00017181919,0.0019633544,0.0043477453,0.06329961,0.9125181],"study_design_scores_gemma":[0.00005082209,0.00016149979,0.0011481084,0.005019624,0.00019202512,0.00081910763,0.00014502104,0.00007679288,0.00024227095,0.0027706313,0.989354,0.000020027692],"about_ca_topic_score_codex":0.0010377987,"about_ca_topic_score_gemma":0.0027690767,"teacher_disagreement_score":0.0038487727,"about_ca_system_score_codex":0.00052927993,"about_ca_system_score_gemma":0.0010409078,"threshold_uncertainty_score":0.012875378},"labels":[],"label_agreement":null},{"id":"W4411991032","doi":"10.1016/j.seminoncol.2025.152386","title":"MicroRNAs: From Bench to Bedside Applications as Breast Cancer Therapeutics","year":2025,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"MicroRNA in disease regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières; Innovation and Economic Development Trois Rivières","funders":"","keywords":"Medicine; Bench to bedside; microRNA; Breast cancer; Oncology; Cancer; Internal medicine; Medical physics; Gene","score_opus":0.017170853052539438,"score_gpt":0.374751117898492,"score_spread":0.35758026484595257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411991032","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007734863,0.9971244,0.00030613577,0.0006063639,0.00078770804,0.0000037461596,0.000014301155,0.000018049826,0.0010619491],"genre_scores_gemma":[0.0010822396,0.99536103,0.0005485494,0.0009477216,0.00083143543,0.000012769129,0.000038775528,0.0000060470647,0.0011713679],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99966896,0.00008111283,0.000030233377,0.000052369178,0.00012638106,0.00004081792],"domain_scores_gemma":[0.9994562,0.00034032518,0.000045042052,0.000016169877,0.00008045066,0.000061869716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013647979,0.0012891446,0.0016482671,0.0014006904,0.00025703266,0.0016275235,0.0009597479,0.0017246528,0.0042284825],"category_scores_gemma":[0.0015083223,0.0003743912,0.0004691542,0.0017233349,0.0010209962,0.0018477609,0.0012160635,0.0039326046,0.0032148412],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015962606,0.000083172075,0.00011383551,0.006081522,0.000071692935,0.00013692254,0.00005160392,0.00044364677,0.0031055762,0.010331716,0.07508813,0.9043326],"study_design_scores_gemma":[0.00004371478,0.00010917555,0.0003090457,0.0015468454,0.0000644266,0.00047180412,0.00004011482,0.00014490623,0.00068832946,0.0042408425,0.9923206,0.000020138921],"about_ca_topic_score_codex":0.00039252982,"about_ca_topic_score_gemma":0.001249585,"teacher_disagreement_score":0.0042284825,"about_ca_system_score_codex":0.0008011749,"about_ca_system_score_gemma":0.0010344633,"threshold_uncertainty_score":0.014145672},"labels":[],"label_agreement":null},{"id":"W9374102","doi":"","title":"Analyzing Knowledge Management Systems: A Veritistic Approach.","year":2004,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"Semantic Web and Ontologies","field":"Computer Science","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Knowledge management; Usability; Personal knowledge management; Computer science; Knowledge engineering; Epistemology; Organizational learning; Psychology; Human–computer interaction","score_opus":0.021243062821472338,"score_gpt":0.2947792621978632,"score_spread":0.2735361993763909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W9374102","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0056346394,0.0006894884,0.9757815,0.0011259406,0.00007329846,0.00049122114,0.0017226209,0.009757729,0.004723564],"genre_scores_gemma":[0.053298708,0.00034321606,0.94259995,0.000103225415,0.000049076818,0.00072993396,0.0017268559,0.00030117834,0.00084792485],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99364024,0.0036613129,0.0005197486,0.0007724132,0.0012044093,0.00020181142],"domain_scores_gemma":[0.9728009,0.022065496,0.0010224761,0.0018340267,0.001918616,0.0003584019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0149150975,0.0012636087,0.0011355571,0.00527939,0.000897566,0.0045379256,0.002586087,0.000984657,0.009711971],"category_scores_gemma":[0.03255029,0.0009768566,0.0015449926,0.0035184915,0.0012678474,0.0030862277,0.0021518234,0.001549852,0.0018556833],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003107053,0.00029703008,0.010304112,0.0011852187,0.00085773476,0.0002548471,0.000731176,0.068471216,0.00142863,0.06674986,0.023030784,0.82637876],"study_design_scores_gemma":[0.00021247788,0.0001722667,0.0033865457,0.00029471988,0.00031454946,0.0002525953,0.00082981563,0.7731168,0.0019622406,0.18791786,0.031489037,0.000051183],"about_ca_topic_score_codex":0.006542289,"about_ca_topic_score_gemma":0.007876166,"teacher_disagreement_score":0.0149150975,"about_ca_system_score_codex":0.0016711322,"about_ca_system_score_gemma":0.004094742,"threshold_uncertainty_score":0.078879476},"labels":[],"label_agreement":null}]}